

# CITATION REPORT

List of articles citing

**The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population**

**DOI: 10.1186/1471-230x-6-33**  
**BMC Gastroenterology, 2006, 6, 33.**

**Source:** <https://exaly.com/paper-pdf/40310255/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1496	Alcohol and the liver. <b>2007</b> , 23, 283-91		31
1495	In vivo detection of liver steatosis in rats based on impedance spectroscopy. <b>2007</b> , 28, 813-28		12
1494	Incidence and natural course of fatty liver in the general population: the Dionysos study. <b>2007</b> , 46, 1387-91		157
1493	Metabolic and nutritional status changes after 10% weight loss in severely obese patients treated with laparoscopic surgery vs integrated medical treatment. <b>2007</b> , 17, 1592-8		31
1492	Review article: diagnosis and treatment of non-alcoholic fatty liver disease. <b>2008</b> , 28, 503-22		84
1491	Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. <b>2008</b> , 5, 95-106		133
1490	Carotid artery intima-media thickness in nonalcoholic fatty liver disease. <b>2008</b> , 121, 72-8		164
1489	Alcoholic Liver Disease: Clinical and Sonographic Features. <b>2008</b> , 16, 140-149		10
1488	Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery. <b>2008</b> , 7, 364-368		24
1487	Clinical update on non-alcoholic fatty liver disease and steatohepatitis. <b>2008</b> , 7, 157-160		9
1486	Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). <b>2009</b> , 8, S4-S8		199
1485	Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). <b>2009</b> , 8, 89-94		33
1484	The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. <b>2009</b> , 7, 21		98
1483	Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. <b>2009</b> , 49, 1537-44		248
1482	Both insulin resistance and alanine aminotransferase level increase the risks of cardiovascular disease in fatty liver disease. <b>2009</b> , 50, 989; author reply 989-90		
1481	Reply:. <b>2009</b> , 50, 989-990		
1480	Noninvasive evaluation of abdominal fat and liver changes following progressive weight loss in severely obese patients treated with laparoscopic gastric bypass. <b>2009</b> , 19, 1664-71		13

1479	Age-related changes in total and regional fat distribution. <b>2009</b> , 8, 339-48		407
1478	Significance of ALT/AST ratio for specifying subjects with metabolic syndrome in its silent stage. <b>2009</b> , 3, 3-6		11
1477	Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. <b>2009</b> , 136, 477-85.e11		263
1476	Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. <b>2009</b> , 137, 865-72		469
1475	Nonalcoholic fatty liver disease: a practical approach to evaluation and management. <b>2009</b> , 13, 249-66		48
1474	The importance of fatty liver disease in clinical practice. <b>2010</b> , 69, 518-27		13
1473	Noninvasive liver steatosis quantification using MRI techniques combined with blood markers. <b>2010</b> , 22, 973-82		22
1472	Metabolically healthy but obese individuals: relationship with hepatic enzymes. <b>2010</b> , 59, 20-4		89
1471	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. <b>2010</b> , 51, 1209-17		445
1470	Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. <b>2010</b> , 52, 913-24		309
1469	Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. <b>2010</b> , 52, 2206-15		55
1468	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. <i>BMC Gastroenterology</i> , <b>2010</b> , 10, 102	3	46
1467	Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. <i>BMC Gastroenterology</i> , <b>2010</b> , 10, 56	3	97
1466	A simple index of lipid overaccumulation is a good marker of liver steatosis. <i>BMC Gastroenterology</i> , <b>2010</b> , 10, 98	3	140
1465	Traditional anthropometric parameters still predict metabolic disorders in women with severe obesity. <b>2010</b> , 18, 1026-32		34
1464	C-reactive protein and gamma-glutamyltransferase concentrations in relation to the prevalence of type 2 diabetes diagnosed by glucose or HbA1c criteria in Chinese adults in Qingdao, China. <b>2010</b> , 2010, 761715		2
1463	Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. <b>2010</b> , 42, 503-8		493
1462	HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. <b>2010</b> , 138, 905-12		203

1461	A position statement on NAFLD/NASH based on the EASL 2009 special conference. <b>2010</b> , 53, 372-84	726
1460	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. <b>2010</b> , 53, 927-33	51
1459	Distribution of abdominal adipose tissue as a predictor of hepatic steatosis assessed by MRI. <b>2010</b> , 65, 695-700	15
1458	Ultrasound imaging in an experimental model of fatty liver disease and cirrhosis in rats. <b>2010</b> , 6, 6	19
1457	The Finnish Diabetes Risk Score (FINDRISC) and other non-invasive scores for screening of hepatic steatosis and associated cardiometabolic risk. <b>2011</b> , 43, 413-7	11
1456	The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. <b>2011</b> , 43, 487-94	18
1455	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. <b>2011</b> , 55, 1409-14	65
1454	Risk factors and predictors of non-alcoholic fatty liver disease in Taiwan. <b>2011</b> , 10, 125-132	27
1453	Biochemical parameters and anthropometry predict NAFLD in obese children. <b>2011</b> , 53, 590-3	26
1452	Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-study. <b>2011</b> , 6, e22932	46
1451	Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <b>2011</b> , 33, 525-40	215
1450	Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. <b>2011</b> , 34, 274-85	2020
1449	High leptin/adiponectin ratio and serum triglycerides are associated with an "at-risk" phenotype in young severely obese patients. <b>2011</b> , 19, 1492-6	53
1448	Relations of adiponectin to levels of metabolic parameters and sexual hormones in elderly type 2 diabetic patients. <b>2011</b> , 8, 93-102	11
1447	Why does NAFLD predict type 2 diabetes?. <b>2011</b> , 11, 167-72	26
1446	Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. <b>2011</b> , 9, 85	211
1445	Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. <b>2011</b> , 54, 145-52	164
1444	Mortality in nonalcoholic fatty liver disease: clues from the Cremona study. <b>2011</b> , 54, 6-8	7

1443	ASH and NASH. <b>2011</b> , 29, 202-10	59
1442	Commentary: Liver enzymes and the risk of adverse cardiovascular outcomes--the lower, the better?. <b>2011</b> , 40, 1539-41	8
1441	Effect of exercise training and isoflavones on hepatic steatosis in overweight postmenopausal women. <b>2013</b> , 16, 88-95	20
1440	Diagnosis and evaluation of nonalcoholic fatty liver disease. <b>2012</b> , 2012, 145754	145
1439	Long-term dietary potential renal acid load during adolescence is prospectively associated with indices of nonalcoholic fatty liver disease in young women. <b>2012</b> , 142, 313-9	20
1438	The alanine aminotransferase to triglycerides ratio as a marker to identify nonalcoholic fatty liver disease. <b>2012</b> , 24, 1173-7	9
1437	Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. <b>2012</b> , 36, 772-81	156
1436	Fatty liver index as an indicator of metabolic syndrome. <b>2012</b> , 45, 68-71	20
1435	Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. <b>2012</b> , 10, 1162-8; quiz e87	52
1434	Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. <b>2012</b> , 11, 513-20	27
1433	Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. <b>2012</b> , 57, 1305-11	144
1432	Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. <b>2012</b> , 32, 629-34	38
1431	Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. <b>2012</b> , 32, 902-10	222
1430	Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. <b>2012</b> , 32, 911-8	233
1429	Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. <b>2012</b> , 57, 392-8	38
1428	Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. <b>2012</b> , 81, e325-31	144
1427	The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 111	3 50
1426	Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 84	3 24

1425	Associations of sex hormone-binding globulin and testosterone with diabetes among men and women (the Saku Diabetes study): a case control study. <b>2012</b> , 11, 130		25
1424	Commentary: Physical activity and NAFLD--cause or effect?. <b>2012</b> , 36, 1097-8; discussion 1098-9		3
1423	Commentary: physical activity and NAFLD - cause or effect? Authors' reply. <b>2012</b> , 36, 1098-1099		0
1422	Can NASH be diagnosed, graded, and staged noninvasively?. <b>2012</b> , 16, 567-85		53
1421	The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. <b>2012</b> , 36, 13-20		157
1420	[Early detection of chronic liver disease in primary care in the apparently health adult population]. <b>2012</b> , 35 Suppl 2, 23-9		1
1419	Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. <b>2012</b> , 55, 1406-15		103
1418	Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. <b>2012</b> , 22, 855-63		24
1417	Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. <b>2012</b> , 47, 696-703		39
1416	Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. <b>2012</b> , 271, 294-304		55
1415	Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. <b>2012</b> , 76, 499-505		14
1414	Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. <b>2012</b> , 19, 244-53		142
1413	Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients. <i>BMC Gastroenterology</i> , <b>2013</b> , 13, 110	3	21
1412	The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients. <b>2013</b> , 7, 592-9		15
1411	Fatty liver score and 15-year incidence of type 2 diabetes. <b>2013</b> , 7, 610-21		9
1410	Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. <b>2013</b> , 56, 2266-74		100
1409	Fatty liver disease index: a simple screening tool to facilitate diagnosis of nonalcoholic fatty liver disease in the Chinese population. <b>2013</b> , 58, 3326-34		17
1408	Non-alcoholic fatty liver disease and cardiovascular risk. <b>2013</b> , 167, 1109-17		64

1407	Noninvasive evaluation of NAFLD. <b>2013</b> , 10, 666-75	198
1406	A common haplotype of carnitine palmitoyltransferase 1b is associated with the metabolic syndrome. <b>2013</b> , 109, 810-5	15
1405	No significant association between vitamin D and nonalcoholic fatty liver disease in a Chinese population. <b>2013</b> , 58, 2376-82	26
1404	Early growth and non-alcoholic fatty liver disease in adulthood-the NAFLD liver fat score and equation applied on the Helsinki Birth Cohort Study. <b>2013</b> , 45, 430-7	90
1403	Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. <b>2013</b> , 21, 583-90	45
1402	NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis. <b>2013</b> , 10, 510-1	24
1401	Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. <b>2013</b> , 28, 142-7	66
1400	Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses. <b>2013</b> , 59, 351-7	104
1399	High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. <b>2013</b> , 58, 557-63	83
1398	Three-year's changes in glucose tolerance status in the Bellville South cohort: rates and phenotypes associated with progression. <b>2013</b> , 99, 223-30	12
1397	Non-alcoholic fatty liver disease in diabetics--prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. <b>2013</b> , 28, 1375-83	52
1396	External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. <b>2013</b> , 11, 1201-4	128
1395	Noninvasive methods of assessing nonalcoholic fatty liver disease: what the clinician needs to know. <b>2013</b> , 11, 1205-7	4
1394	The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. <b>2013</b> , 227, 398-403	28
1393	Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. <b>2013</b> , 37, 392-400	126
1392	Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. <b>2013</b> , 45, 162-70	46
1391	Assessment of the fatty liver index as an indicator of hepatic steatosis for predicting incident diabetes independently of insulin resistance in a Korean population. <b>2013</b> , 30, 428-35	30
1390	Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. <b>2013</b> , 58, 1007-19	259

1389	Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. <b>2013</b> , 5, 1544-60	474
1388	Non-Invasive Methods to Determine the Severity of NAFLD and NASH. <b>2013</b> , 112-121	
1387	Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). <b>2013</b> , 37, 353-8	29
1386	Lifestyle interventions for the treatment of non-alcoholic fatty liver disease. <b>2014</b> , 6, 1-10	5
1385	Non-alcoholic fatty liver disease: factors associated with its presence and onset. <b>2013</b> , 28 Suppl 4, 71-8	18
1384	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <b>2013</b> , 66, 1033-45	54
1383	A weight loss diet intervention has a similar beneficial effect on both metabolically abnormal obese and metabolically healthy but obese premenopausal women. <b>2013</b> , 62, 223-30	24
1382	Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. <b>2013</b> , 38, 1267-77	110
1381	Higher fetuin-A level is associated with coexistence of elevated alanine aminotransferase and the metabolic syndrome in the general population. <b>2013</b> , 11, 377-84	3
1380	Prevalence of metabolically discordant phenotypes in a mediterranean population-The IMAP study. <b>2013</b> , 19, 758-68	4
1379	Noninvasive markers for the diagnosis of nonalcoholic Fatty liver disease. <b>2013</b> , 28, 280-2	4
1378	Association of serum adipocyte-specific Fatty Acid binding protein with Fatty liver index as a predictive indicator of nonalcoholic Fatty liver disease. <b>2013</b> , 28, 283-7	11
1377	The role of skeletal muscle in development of nonalcoholic Fatty liver disease. <b>2013</b> , 37, 278-85	48
1376	Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. <b>2013</b> , 12, 405-16	35
1375	Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. <b>2013</b> , 8, e72049	54
1374	Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The VARESI Italian multicenter study. <b>2013</b> , 12, 70-77	13
1373	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. <b>2013</b> , 19, 57-64	77
1372	Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. <b>2014</b> , 9, e91987	89



1371	Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. <b>2014</b> , 9, e94059	88
1370	Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. <b>2014</b> , 9, e104941	23
1369	Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. <b>2014</b> , 9, e107584	53
1368	Is non-alcoholic fatty liver disease less frequent among women with Prader-Willi syndrome?. <b>2014</b> , 7, 71-6	19
1367	Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. <b>2014</b> , 29, 973-9	17
1366	Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. <b>2014</b> , 20, 14172-84	54
1365	Physical activity support or weight loss counseling for nonalcoholic fatty liver disease?. <b>2014</b> , 20, 10128-36	19
1364	Diagnosis of Non-alcoholic Fatty Liver Disease. <b>2014</b> , 15, 82	
1363	Biochemical, anthropometric and body composition indicators as predictors of hepatic steatosis in obese adolescents. <b>2014</b> , 32, 230-6	
1362	Nonalcoholic fatty liver disease and polycystic ovary syndrome. <b>2014</b> , 20, 8351-63	80
1361	Non-alcoholic fatty liver disease: what the clinician needs to know. <b>2014</b> , 20, 12956-80	117
1360	Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. <b>2014</b> , 20, 4702-11	77
1359	Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD). <b>2014</b> , 357-372	1
1358	Non-alcoholic fatty liver disease: diagnosis and investigation. <b>2014</b> , 32, 586-96	8
1357	Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA. <b>2014</b> , 12, 154	32
1356	Serum vitamin D is associated with non-alcoholic fatty liver disease in Chinese males with normal weight and liver enzymes. <b>2014</b> , 35, 1150-6	20
1355	Serum fetuin-A concentration predicts glycaemic outcomes in people with prediabetes: a prospective study from eastern India. <b>2014</b> , 31, 1594-9	22
1354	Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <b>2014</b> , 29, 2006-13	35

1353	Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease. <b>2014</b> , 29, 1528-34	12
1352	Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. <b>2014</b> , 40, 1209-22	196
1351	Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. <b>2014</b> , 29, 1508-14	27
1350	Low serum sex hormone-binding globulin is associated with nonalcoholic fatty liver disease in type 2 diabetic patients. <b>2014</b> , 80, 877-83	40
1349	Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. <b>2014</b> , 100, 1133-8	45
1348	A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. <b>2014</b> , 9, e105192	103
1347	External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. <b>2014</b> , 171, 561-9	80
1346	Comparison of serum ferritin and vitamin d in association with the severity of nonalcoholic Fatty liver disease in korean adults. <b>2014</b> , 29, 479-88	10
1345	Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <b>2014</b> , 34, 102-9	113
1344	Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. <b>2014</b> , 24, 670-6	27
1343	The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. <b>2014</b> , 18, 233-48	15
1342	The FTO gene polymorphism (rs9939609) is associated with metabolic syndrome in morbidly obese subjects from southern Italy. <b>2014</b> , 28, 195-9	20
1341	How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. <b>2014</b> , 34, e111-7	52
1340	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <b>2014</b> , 90, 254-66	7
1339	Accelerated infant weight gain and risk for nonalcoholic fatty liver disease in early adulthood. <b>2014</b> , 99, 1189-95	35
1338	[Non-invasive markers of fibrosis in the diagnosis of non-alcoholic fatty liver disease]. <b>2014</b> , 37, 503-10	5
1337	Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. <b>2014</b> , 60, 1026-31	241
1336	Using Participant Similarity for the Classification of Epidemiological Data on Hepatic Steatosis. <b>2014</b> ,	7

1335	Deterioration, improvement of kidney function over time and determinants in the Cape Town Bellville South cohort. <b>2014</b> , 19, 638-47	1
1334	Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. <b>2014</b> , 100, 833-49	157
1333	Noninvasive prediction of hepatic steatosis. <b>2014</b> , 109, 1415-6	2
1332	Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. <b>2014</b> , 109, 1404-14	60
1331	Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. <b>2014</b> , 37, 739-744	10
1330	Liver in the analysis of body composition by dual-energy X-ray absorptiometry. <b>2014</b> , 87, 20140232	6
1329	Relationship between testosterone, sex hormone binding globulin, angiotensin related growth factor and insulin resistance in normal weight and obese men Available online 5 December 2013 View all notes Peer review under responsibility of Alexandria University Faculty of Medicine. View all notes. <b>2014</b> , 50, 37-44	
1328	Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. <b>2014</b> , 46, 720-5	26
1327	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. <b>2014</b> , 20, 1724-45	160
1326	Clinical approaches to non-alcoholic fatty liver disease. <b>2014</b> , 20, 1712-23	95
1325	Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <b>2014</b> , 20, 475-85	296
1324	Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes. <b>2015</b> , 6, 309-16	16
1323	Nonalcoholic fatty liver disease. <b>2015</b> , 1, 15080	366
1322	Sex-Specific Predictors of Metabolic Syndrome Independent of Its Components. <b>2015</b> , 63, 796-801	6
1321	[Non-invasive assessment of fatty liver]. <b>2015</b> , 156, 543-51	1
1320	ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. <b>2015</b> , 5, 16494	44
1319	Late gestation under- and overnutrition have differential impacts when combined with a post-natal obesogenic diet on glucose-lactate-insulin adaptations during metabolic challenges in adolescent sheep. <b>2015</b> , 213, 519-36	12
1318	Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. <b>2015</b> , 13, 303	46

1317	Should we assess cardiovascular risk in young adults born preterm?. <b>2015</b> , 26, 282-7	9
1316	Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese. <b>2015</b> , 94, e1682	81
1315	Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <b>2015</b> , 133, 115-24	15
1314	Elevated Serum Gamma-glutamyl Transpeptidase Levels and Fatty Liver Strongly Predict the Presence of Carotid Plaque. <b>2015</b> , 22, 1051-60	5
1313	External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. <b>2015</b> , 10, e0120443	61
1312	Associations of Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver Fat Accumulation in the EPIC-Potsdam Study. <b>2015</b> , 10, e0127368	18
1311	High Dietary Sodium Intake Assessed by Estimated 24-h Urinary Sodium Excretion Is Associated with NAFLD and Hepatic Fibrosis. <b>2015</b> , 10, e0143222	26
1310	Quantification of Hepatorenal Index for Computer-Aided Fatty Liver Classification with Self-Organizing Map and Fuzzy Stretching from Ultrasonography. <b>2015</b> , 2015, 535894	2
1309	Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. <b>2015</b> , 3, 230-8	30
1308	Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. <b>2015</b> , 14, 826-36	16
1307	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. <b>2015</b> , 9, 1039-53	9
1306	Volume-dependent effect of supervised exercise training on fatty liver and visceral adiposity index in subjects with type 2 diabetes The Italian Diabetes Exercise Study (IDES). <b>2015</b> , 109, 355-63	24
1305	Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. <b>2015</b> , 21, 64-70	18
1304	Serum Fetuin-A Associated With Fatty Liver Index, Early Indicator of Nonalcoholic Fatty Liver Disease: A Strobe-Compliant Article. <b>2015</b> , 94, e1517	9
1303	Television viewing and fatty liver in early midlife. The Cardiovascular Risk in Young Finns Study. <b>2015</b> , 47, 519-26	12
1302	Risk for Nonalcoholic Fatty Liver Disease in Young Adults Born Preterm. <b>2015</b> , 84, 199-205	9
1301	Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. <b>2015</b> , 41, 65-76	140
1300	Editorial: utility and pitfalls of Fatty Liver Index in epidemiologic studies for the diagnosis of NAFLD. <b>2015</b> , 41, 406-7	11

1299	Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. <b>2015</b> , 33, 743-51	19
1298	The UCP2 -866'G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. <b>2015</b> , 35, 1574-80	35
1297	Mediterranean diet. <b>2015</b> , 112, 143	
1296	Reply to: "protective effects of moderate alcohol consumption on fatty liver: a spurious association?". <b>2015</b> , 62, 1211-2	
1295	γ-Glutamyl Transferase Is Associated with Mortality Outcomes Independently of Fatty Liver. <b>2015</b> , 61, 1173-81	15
1294	Cardiometabolic risk factors in young adults who were born preterm. <b>2015</b> , 181, 861-73	139
1293	Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome. <b>2015</b> , 72, 16-24	17
1292	Age at menarche and non-alcoholic fatty liver disease. <b>2015</b> , 62, 1164-70	37
1291	Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. <b>2015</b> , 15, 607	74
1290	Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. <b>2015</b> , 38, 1347-55	121
1289	Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study. <b>2015</b> , 27, 305-12	8
1288	Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: The PREVENT study. <b>2015</b> , 243, 138-47	31
1287	Increased circulating adiponectin in males with chronic HCV hepatitis. <b>2015</b> , 26, 635-9	5
1286	Predicting hepatic steatosis and liver fat content in obese children based on biochemical parameters and anthropometry. <b>2015</b> , 10, 112-7	7
1285	Interobserver variability in transient elastography analysis of patients with chronic hepatitis C. <b>2015</b> , 35, 1533-9	22
1284	Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. <b>2015</b> , 63, 1229-37	116
1283	Evaluation of various biomarkers as potential mediators of the association between 5 $\alpha$ -desaturase, 6 $\alpha$ -desaturase, and stearyl-CoA desaturase activity and incident type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. <b>2015</b> , 102, 155-64	38
1282	Protective effects of moderate alcohol consumption on fatty liver: a spurious association?. <b>2015</b> , 62, 1209-11	2

1281	Inverse relationship between serum osteocalcin levels and nonalcoholic fatty liver disease in postmenopausal Chinese women with normal blood glucose levels. <b>2015</b> , 36, 1497-502	19
1280	Ageing, adipose tissue, fatty acids and inflammation. <b>2015</b> , 16, 235-48	62
1279	Chronic liver disease in the human immunodeficiency virus patient. <b>2015</b> , 19, 1-22	13
1278	Prediabetes and associated disorders. <b>2015</b> , 48, 371-93	86
1277	Prevalence of Reduced Kidney Function by Estimated Glomerular Filtration Rate Using an Equation Based on Creatinine and Cystatin C in Metabolic Syndrome and Its Components in Korean Adults. <b>2016</b> , 31, 446-453	4
1276	Non-alcoholic fatty liver disease-From the cardiologist perspective. <b>2016</b> , 16, 534-41	9
1275	Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. <b>2016</b> , 22, 327-335	42
1274	Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients. <b>2016</b> , 16, e40263	13
1273	The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. <b>2016</b> , 2016, 2931985	42
1272	Objectively Quantified Physical Activity and Sedentary Behavior in Predicting Visceral Adiposity and Liver Fat. <b>2016</b> , 2016, 2719014	14
1271	Additive Effect of Non-Alcoholic Fatty Liver Disease on Metabolic Syndrome-Related Endothelial Dysfunction in Hypertensive Patients. <b>2016</b> , 17, 456	18
1270	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. <b>2016</b> , 11, e0162473	34
1269	Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing. <b>2016</b> , 11, e0149564	146
1268	Metformin Changes the Relationship between Blood Monocyte Toll-Like Receptor 4 Levels and Nonalcoholic Fatty Liver Disease-Ex Vivo Studies. <b>2016</b> , 11, e0150233	5
1267	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. <b>2016</b> , 11, e0157358	44
1266	Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. <b>2016</b> , 11, e0158066	8
1265	To Assess the Association between Glucose Metabolism and Ectopic Lipid Content in Different Clinical Classifications of PCOS. <b>2016</b> , 11, e0160571	9
1264	Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population. <b>2016</b> , 89, 82-8	14

1263	Clinical guidelines of non-alcoholic fatty liver disease: A systematic review. <b>2016</b> , 22, 8226-33	20
1262	Obstructive sleep apnea is associated with fatty liver index, the index of nonalcoholic fatty liver disease. <b>2016</b> , 28, 650-5	9
1261	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <b>2016</b> , 31, 848-55	106
1260	Gamma glutamyl transferase 'To be or not to be' a liver function test?. <b>2016</b> , 53, 629-631	10
1259	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. <b>2016</b> , 63, 787-98	70
1258	Discriminatory value of alanine aminotransferase for diabetes prediction: the Insulin Resistance Atherosclerosis Study. <b>2016</b> , 33, 348-55	7
1257	Effects of Eating Fast and Eating Before Bedtime on the Development of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 19, 279-83	10
1256	Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. <b>2016</b> , 311, G1009-G1017	53
1255	Short-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation Parameter. <b>2016</b> , 7, e176	23
1254	Dietary sodium and potassium intake in relation to non-alcoholic fatty liver disease. <b>2016</b> , 116, 1447-1456	43
1253	Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study. <b>2016</b> , 6, 38262	42
1252	Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD. <b>2016</b> , 6, 24740	13
1251	How to best diagnose NAFLD/NASH?. <b>2016</b> , 111-123	
1250	Are the advantages of obtaining a liver biopsy outweighed by the disadvantages?. <b>2016</b> , 152-160	1
1249	Screening for NAFLD in high-risk populations. <b>2016</b> , 161-170	
1248	Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection. <b>2016</b> , 6, 32875	12
1247	A fatty liver leads to a broken heart?. <b>2016</b> , 65, 14-16	3
1246	Association between erythrocyte omega-3 polyunsaturated fatty acid levels and fatty liver index in older people is sex dependent. <b>2016</b> , 5, 78-85	7

1245	Gamma glutamyltransferase and risk of future dementia in middle-aged to older Finnish men: A new prospective cohort study. <b>2016</b> , 12, 931-941	27
1244	Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas. <b>2016</b> , 19, 461-71	10
1243	Effect of the three-dimensional organization of liver cells on the biogenesis of the Eglutamyltransferase fraction pattern. <b>2016</b> , 21, 441-8	2
1242	Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis. <b>2016</b> , 14, 1172-1180.e2	29
1241	Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. <b>2016</b> , 31, 1347-53	64
1240	Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. <b>2016</b> , 15, 86-95	16
1239	The association between sarcopenia and non-alcoholic fatty liver disease: Potential pitfalls in non-invasive prediction models. <b>2016</b> , 64, 519-520	1
1238	Fatty liver is an independent predictor of early carotid atherosclerosis. <b>2016</b> , 65, 95-102	67
1237	Visceral adipose tissue dysfunction and mortality among a population-based sample of males and females. <b>2016</b> , 42, 382-385	7
1236	Hepatic Biomarkers in Diabetes as Modulated by Dietary Phytochemicals. <b>2016</b> , 1-19	
1235	Benign Prostatic Hyperplasia, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: Is Metaflammation the Link?. <b>2016</b> , 76, 1528-1535	24
1234	Mid-infrared fibre evanescent wave spectroscopy of serum allows fingerprinting of the hepatic metabolic status in mice. <b>2016</b> , 141, 6259-6269	4
1233	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. <b>2016</b> , 233, 3947-3952	26
1232	Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with Type 2 diabetes. <b>2016</b> , 130, 1753-62	13
1231	Uterine fibroids and cardiovascular risk. <b>2016</b> , 31, 2689-2703	18
1230	Fettleberdiagnostik bei Diabetes mellitus Typ 2. <b>2016</b> , 12, 473-477	
1229	Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG study. <b>2016</b> , 95, e4447	27
1228	Fatty liver index is a risk determinant of incident type 2 diabetes in a metabolically healthy population with obesity. <b>2016</b> , 24, 1373-9	26



1227	No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. <b>2016</b> , 14, 92	86
1226	Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. <b>2016</b> , 111, 658-64	49
1225	Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea National Health and Nutrition Examination Survey. <b>2016</b> , 15, 39-47	33
1224	Evaluation of abnormal liver function tests. <b>2016</b> , 92, 223-34	59
1223	The Correlation Between Obesity-Related Diseases and Non-alcoholic Fatty Liver Disease in Women in the Pre-operative Evaluation for Bariatric Surgery Assessed by Transient Hepatic Elastography. <b>2016</b> , 26, 2089-2097	9
1222	Serum palmitoleate acts as a lipokine in subjects at high cardiometabolic risk. <b>2016</b> , 26, 261-7	7
1221	Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. <b>2016</b> , 10, 63-71	37
1220	T-cadherin gene variants are associated with type 2 diabetes and the Fatty Liver Index in the French population. <b>2017</b> , 43, 33-39	13
1219	Non-alcoholic fatty liver disease and diabetes. <b>2017</b> , 148, 33-38	2
1218	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <b>2017</b> , 49, 471-483	179
1217	Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: Interrelationship with age. <b>2017</b> , 466, 54-60	17
1216	An extended fatty liver index to predict non-alcoholic fatty liver disease. <b>2017</b> , 43, 229-239	18
1215	A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. <b>2017</b> , 10, 207-217	35
1214	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. <b>2017</b> , 40, 419-430	172
1213	Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia. <b>2017</b> , 11, 551-561.e7	13
1212	Diagnóstico de esteatosis hepática por métodos clínicos, bioquímicos y por imágenes. <b>2017</b> , 54, 37-46	1
1211	Intrahepatic fat, abdominal adipose tissues, and metabolic state: magnetic resonance imaging study. <b>2017</b> , 33, e2888	10
1210	Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. <b>2017</b> , 2, 211-223	22

1209	Changes in fatty liver index after consuming a Mediterranean diet: 6-year follow-up of the PREDIMED-Malaga trial. <b>2017</b> , 148, 435-443	15
1208	Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score). <b>2017</b> , 37, 1535-1543	11
1207	Prevalence of polycystic ovary syndrome in Chinese obese women of reproductive age with or without metabolic syndrome. <b>2017</b> , 107, 1048-1054	13
1206	Insulin resistance and normal thyroid hormone levels: prospective study and metabolomic analysis. <b>2017</b> , 312, E429-E436	18
1205	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. <b>2017</b> , 10, 535-547	13
1204	Semaglutide, lipid-lowering drugs, and NAFLD. <b>2017</b> , 5, 329-330	10
1203	Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. <b>2017</b> , 35, 493-500	40
1202	Non-alcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey. <b>2017</b> , 37, 1706-1714	18
1201	How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool. <b>2017</b> , 66, 825-833	25
1200	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. <b>2017</b> , 72, 57-65	80
1199	High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study. <b>2017</b> , 72, 37-46	24
1198	25(OH)D Levels in Relation to Gender, Overweight, Insulin Resistance, and Inflammation in a Cross-Sectional Cohort of Northern Italian Workers: Evidence in Support of Preventive Health Care Programs. <b>2017</b> , 36, 253-260	9
1197	Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study. <b>2017</b> , 67, 62-71	46
1196	The Fatty Liver Index (FLI) Relates to Diabetes-Specific Parameters and an Adverse Lipid Profile in a Cohort of Nondiabetic, Dyslipidemic Patients. <b>2017</b> , 36, 287-294	6
1195	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. <b>2017</b> , 46, 447-456	73
1194	NAFLD in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by H-MRS?. <b>2017</b> , 37, 1907-1915	11
1193	Changes in fatty liver index after consuming a Mediterranean diet: 6-Year follow-up of the PREDIMED-Malaga trial. <b>2017</b> , 148, 435-443	2
1192	Metabolic and androgen profile in underweight women with polycystic ovary syndrome. <b>2017</b> , 296, 363-371	9

1191	A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. <b>2017</b> , 49, 910-917	28
1190	Non-alcoholic fatty liver disease and diabetes. <b>2017</b> , 148, 33-38	
1189	. <b>2017</b> , 19, 1467-1481	18
1188	A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease. <b>2017</b> , 52, 1201-1210	42
1187	Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults on their health check-up. <b>2017</b> , 18, 229-236	11
1186	Indicators of fetal growth and adult liver enzymes: the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study. <b>2017</b> , 8, 226-235	3
1185	Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia. <b>2017</b> , 20, 79-85	14
1184	Occurrence over time and regression of nonalcoholic fatty liver disease in type 2 diabetes. <b>2017</b> , 33, e2878	15
1183	Relative contribution of muscle and liver insulin resistance to dysglycemia in postmenopausal overweight and obese women: A MONET group study. <b>2017</b> , 78, 1-8	2
1182	NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver. <b>2017</b> , 475, 44-50	5
1181	Association between hemoglobin glycation index and hepatic steatosis in non-diabetic individuals. <b>2017</b> , 134, 53-61	17
1180	Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population. <b>2017</b> , 46, 559-560	0
1179	Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease. <b>2017</b> , 58, 246-252	11
1178	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. <b>2017</b> , 12, 1159-1165	11
1177	Esteatosis hepática: diagnóstico y seguimiento. <b>2017</b> , 24, 378-389	0
1176	Sleep duration and progression to diabetes in people with prediabetes defined by HbA concentration. <b>2017</b> , 34, 1591-1598	11
1175	External validation of non-invasive prediction models for identifying ultrasonography-diagnosed fatty liver disease in a Chinese population. <b>2017</b> , 96, e7610	14
1174	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. <b>2017</b> , 24, 1870-1877	33

1173	Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients. <b>2017</b> , 47, 829-838	8
1172	Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. <b>2017</b> , 8, 1785	192
1171	The ZJU index is a powerful index for identifying NAFLD in the general Chinese population. <b>2017</b> , 54, 905-911	10
1170	Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter. <i>BMC Gastroenterology</i> , <b>2017</b> , 17, 61	3 40
1169	Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction. <b>2017</b> , 105, 127-135	80
1168	Effect of a Low Glycemic Index Mediterranean Diet on Non-Alcoholic Fatty Liver Disease. A Randomized Controlled Clinici Trial. <b>2017</b> , 21, 404-412	60
1167	Non-invasive diagnosis of hepatic steatosis. <b>2017</b> , 11, 70-78	64
1166	Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. <b>2017</b> , 40, 109-116	33
1165	Short sleep duration and longer daytime napping are associated with non-alcoholic fatty liver disease in Chinese adults. <b>2017</b> , 9, 827-836	23
1164	Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients. <b>2017</b> , 65, 465-474	23
1163	Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. <b>2017</b> , 47, 522-532	16
1162	Serum endotrophin identifies optimal responders to PPAR $\alpha$ agonists in type 2 diabetes. <b>2017</b> , 60, 50-59	34
1161	Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. <b>2017</b> , 1, 899-910	25
1160	Bioavailable testosterone is independently associated with Fatty Liver Index in postmenopausal women. <b>2017</b> , 13, 1188-1196	19
1159	Carbohydrates from Sources with a Higher Glycemic Index during Adolescence: Is Evening Rather than Morning Intake Relevant for Risk Markers of Type 2 Diabetes in Young Adulthood?. <b>2017</b> , 9,	12
1158	Fruit Fiber Consumption Specifically Improves Liver Health Status in Obese Subjects under Energy Restriction. <b>2017</b> , 9,	41
1157	Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. <b>2017</b> , 9,	55
1156	Iso-caloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. <b>2017</b> , 9,	35

1155	Detection of Lipid and Amphiphilic Biomarkers for Disease Diagnostics. <b>2017</b> , 7,	20
1154	Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. <b>2017</b> , 64, 363-367	61
1153	Nonalcoholic fatty liver disease: Evolving paradigms. <b>2017</b> , 23, 6571-6592	92
1152	Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. <b>2017</b> , 23, 3150-3162	60
1151	Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort. <b>2017</b> , 12, e0171502	54
1150	The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. <b>2017</b> , 12, e0180951	31
1149	Non-alcoholic fatty liver disease as a risk factor for female sexual dysfunction in premenopausal women. <b>2017</b> , 12, e0182708	2
1148	Ideal cardiovascular health predicts lower risk of abnormal liver enzymes levels in the Chilean National Health Survey (2009-2010). <b>2017</b> , 12, e0185908	3
1147	Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. <b>2017</b> , 12, e0173499	142
1146	Diagnosis of Non-Alcoholic Fatty Liver Disease Based on Clinical and Laboratory Data. <b>2017</b> , 18, 102	4
1145	Metabolically healthy obesity: a friend or foe?. <b>2017</b> , 32, 611-621	76
1144	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. <b>2017</b> , 2017, 9279836	9
1143	Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. <b>2018</b> , 34, e2998	4
1142	Obesity and Nonalcoholic Fatty Liver Disease. <b>2018</b> , 89-97	1
1141	Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controls. <b>2018</b> , 32, e13240	1
1140	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <b>2018</b> , 41, 328-349	30
1139	Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. <b>2018</b> , 58, 28-36	21
1138	High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. <b>2018</b> , 16, 1138-1145.e5	91

1137	Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. <b>2018</b> , 68, 1063-1075	346
1136	Risk for the development of non-alcoholic fatty liver disease: A prospective study. <b>2018</b> , 33, 1518-1523	7
1135	Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. <b>2018</b> , 38 Suppl 1, 47-51	198
1134	Fatty liver index, albuminuria and the association with chronic kidney disease: a population-based study in China. <b>2018</b> , 8, e019097	10
1133	Fatty liver index predicts incident diabetes in a Japanese general population with and without impaired fasting glucose. <b>2018</b> , 48, 708-716	9
1132	Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. <b>2018</b> , 50, 370-377	29
1131	European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. <b>2018</b> , 35, 368-375	50
1130	Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. <b>2018</b> , 68, 1018-1024	67
1129	Role of fatty liver in the association between obesity and reduced hepatic insulin clearance. <b>2018</b> , 44, 135-142	12
1128	Metabolically healthy obesity without fatty liver and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies. <b>2018</b> , 12, 4-15	22
1127	Periodontitis and prevalence of elevated aminotransferases in the Hispanic Community Health Study/Study of Latinos. <b>2018</b> , 89, 949-958	12
1126	The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients. <b>2018</b> , 45, 668-674	14
1125	Computed tomographic evaluation of the thymus-does obesity affect thymic fatty involution in a healthy young adult population?. <b>2018</b> , 91, 20170609	5
1124	Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study. <b>2018</b> , 53, 29-33	20
1123	Waist circumference is a mediator of dietary pattern in Non-alcoholic fatty liver disease. <b>2018</b> , 8, 4788	12
1122	Components of metabolic syndrome in relation to plasma levels of retinol binding protein 4 (RBP4) in a cohort of people aged 65 years and older. <b>2018</b> , 41, 1211-1219	12
1121	Markers of hepatic fibrosis. <b>2018</b> , 150, 310-316	
1120	Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. <b>2018</b> , 33, 270-276	50

1119	Dietary Inflammatory Index and liver status in subjects with different adiposity levels within the PREDIMED trial. <b>2018</b> , 37, 1736-1743	28
1118	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <b>2018</b> , 33, 70-85	211
1117	The relationship between fatty liver index and bone mineral density in Koreans: KNHANES 2010-2011. <b>2018</b> , 29, 181-190	10
1116	Is there a J-shaped relationship between the fatty liver index and risk of microalbuminuria in the general population?. <b>2018</b> , 481, 231-237	3
1115	Associations between dietary factors and markers of NAFLD in a general Dutch adult population. <b>2018</b> , 72, 117-123	36
1114	Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. <b>2018</b> , 50, 68-75	18
1113	Markers of hepatic fibrosis. <b>2018</b> , 150, 310-316	7
1112	Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients. <b>2018</b> , 135, 65-72	12
1111	NAFLD/NASH in patients with type 2 diabetes and related treatment options. <b>2018</b> , 41, 509-521	32
1110	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <b>2018</b> , 12, 351-367	34
1109	The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. <b>2018</b> , 61, 36-42	9
1108	A composite noninvasive index correlates with liver fibrosis scores in post-Fontan patients: Preliminary findings. <b>2018</b> , 13, 38-45	13
1107	Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. <b>2018</b> , 12, 539-548	18
1106	Cross-sectional associations of albuminuria among Aboriginal and Torres Strait Islander adults: the eGFR Study. <b>2018</b> , 23, 37-45	3
1105	Thyroid Function and Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects. <b>2018</b> , 17, 779-788	26
1104	HIV and the Liver. <b>2018</b> , 536-555.e7	1
1103	Application of Machine Learning Techniques for Clinical Predictive Modeling: A Cross-Sectional Study on Nonalcoholic Fatty Liver Disease in China. <b>2018</b> , 2018, 4304376	40
1102	Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. <b>2018</b> , 7,	8

1101	Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: A review. <b>2018</b> , 10, 695-701	9
1100	Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. <b>2019</b> , 392, 2705-2717	227
1099	Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. <b>2018</b> , 10,	98
1098	Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. <i>BMC Gastroenterology</i> , <b>2018</b> , 18, 177	3 15
1097	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <b>2018</b> , 69, 1155-1163	25
1096	Liver fat scores predict liver disease mortality in the United States population. <b>2018</b> , 48, 1003-1016	24
1095	Obesity and Nonalcoholic Fatty Liver Disease: Role of Oxidative Stress. <b>2018</b> , 111-133	4
1094	Serological biomarkers associate ultrasound characteristics of steatohepatitis in mice with liver cancer. <b>2018</b> , 15, 71	6
1093	Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. <b>2018</b> , 13, e0200656	12
1092	Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men. <b>2018</b> , 13, e0201308	25
1091	Changes in Plasma Acylcarnitine and Lysophosphatidylcholine Levels Following a High-Fructose Diet: A Targeted Metabolomics Study in Healthy Women. <b>2018</b> , 10,	18
1090	The fatty liver index (FLI) and incident hypertension: a longitudinal study among Chinese population. <b>2018</b> , 17, 214	12
1089	Predictive Value of Lipid Accumulation Product, Fatty Liver Index, Visceral Adiposity Index for Metabolic Syndrome According to Menopausal Status. <b>2018</b> , 16, 477-482	4
1088	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. <b>2018</b> ,	3
1087	Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. <b>2018</b> , 144, 144-152	14
1086	Production of Elastin-Derived Peptides Contributes to the Development of Nonalcoholic Steatohepatitis. <b>2018</b> , 67, 1604-1615	24
1085	Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. <b>2018</b> , 15, 461-478	206
1084	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <b>2018</b> , 41, 328-349	1



1083	Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. <b>2018</b> , 65, 373-381		10
1082	Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. <b>2018</b> , 44, 373-375		2
1081	Plasma lecithin:cholesterol acyltransferase and phospholipid transfer protein activity independently associate with nonalcoholic fatty liver disease. <b>2018</b> , 48, e12988		11
1080	The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. <b>2018</b> , 50, 371-380		7
1079	Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. <b>2018</b> , 315, G329-G338		20
1078	Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease. <b>2018</b> , 277, 21-27		16
1077	Liver Fat Scores Moderately Reflect Interventional Changes in Liver Fat Content by a Low-Fat Diet but Not by a Low-Carb Diet. <b>2018</b> , 10,		13
1076	Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults. <i>BMC Gastroenterology</i> , <b>2018</b> , 18, 113	3	14
1075	Habitual Fructose Intake Relates to Insulin Sensitivity and Fatty Liver Index in Recent-Onset Type 2 Diabetes Patients and Individuals without Diabetes. <b>2018</b> , 10,		11
1074	MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY. <b>2018</b> , 55, 7-13		8
1073	Changes in lysophospholipids and liver status after weight loss: the RESMENA study. <b>2018</b> , 15, 51		12
1072	Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption. <b>2018</b> , 19, 79		45
1071	Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. <b>2018</b> , 208, 201-207		43
1070	Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome. <b>2018</b> , 116, 1-7		20
1069	Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. <b>2018</b> , 63, 3187-3206		32
1068	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <b>2018</b> , 69, 1349-1356		96
1067	Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. <b>2018</b> , 10,		68
1066	Increased Serum Uric Acid over five years is a Risk Factor for Developing Fatty Liver. <b>2018</b> , 8, 11735		21

1065	Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN). <b>2018</b> , 10,	15
1064	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. <b>2018</b> , 24, 3361-3373	203
1063	Burden of non-alcoholic fatty liver disease in Australia. <b>2018</b> , 33 Suppl 1, 1-11	25
1062	Cognitive Performance in Individuals With Non-Alcoholic Fatty Liver Disease and/or Type 2 Diabetes Mellitus. <b>2018</b> , 59, 567-574	18
1061	Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study. <b>2018</b> , 13, e0198327	23
1060	Alcohol consumption, but not smoking is associated with higher MR-derived liver fat in an asymptomatic study population. <b>2018</b> , 13, e0192448	2
1059	Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. <b>2018</b> , 48, 300-312	25
1058	Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction. <b>2018</b> , 30, 1047-1054	20
1057	Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham Score. <b>2019</b> , 69, 1453-1463	19
1056	Plasma ApoE elevations are associated with NAFLD: The PREVENT Study. <b>2019</b> , 14, e0220659	6
1055	Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). <b>2019</b> , 8,	64
1054	The association of high-normal international-normalized-ratio (INR) with mortality in patients referred for coronary angiography. <b>2019</b> , 14, e0221112	1
1053	Oral Diseases Associated with Nonalcoholic Fatty Liver Disease in the United States. <b>2019</b> , 98, 1219-1226	16
1052	Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin. <b>2019</b> , 66, 995-1000	4
1051	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <b>2019</b> , 153, 169-177	7
1050	Clinical prediction score of nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index). <b>2019</b> , 91, 544-552	12
1049	Association of fatty liver index with risk of incident type 2 diabetes by metabolic syndrome status in an Eastern Finland male cohort: a prospective study. <b>2019</b> , 9, e026949	7
1048	Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients. <b>2019</b> , 147, 104362	3

1047	Depression is associated with non-alcoholic fatty liver disease among adults in the United States. <b>2019</b> , 50, 590-598	30
1046	Associations Between Body Fat, Muscle Mass, and Nonalcoholic Fatty Liver Disease: A Population-Based Study. <b>2019</b> , 3, 1061-1072	12
1045	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. <b>2019</b> , 20,	21
1044	The anti-inflammatory potential of diet and nonalcoholic fatty liver disease: the ATTICA study. <b>2019</b> , 12, 1756284819858039	9
1043	Fasting Glucose State Determines Metabolic Response to Supplementation with Insoluble Cereal Fibre: A Secondary Analysis of the Optimal Fibre Trial (OptiFiT). <b>2019</b> , 11,	13
1042	Visceral adipose accumulation increased the risk of hyperuricemia among middle-aged and elderly adults: a population-based study. <b>2019</b> , 17, 341	13
1041	Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. <b>2019</b> , 20, 580	5
1040	Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. <b>2019</b> , 19, 187-198	10
1039	Obesity Does Not Modulate the Glycometabolic Benefit of Insoluble Cereal Fibre in Subjects with Prediabetes-A Stratified Post Hoc Analysis of the Optimal Fibre Trial (OptiFiT). <b>2019</b> , 11,	8
1038	Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population. <b>2019</b> , 14, e0224626	15
1037	Effects of Periodic Fasting on Fatty Liver Index-A Prospective Observational Study. <b>2019</b> , 11,	27
1036	The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. <b>2019</b> , 11,	26
1035	Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study. <b>2019</b> , 10, 2042018819871169	5
1034	Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight. <b>2019</b> , 14, e0221400	12
1033	Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study. <b>2019</b> , 14, e0221524	16
1032	Adipose lipid turnover and long-term changes in body weight. <b>2019</b> , 25, 1385-1389	46
1031	Associations of short stature and components of height with incidence of type 2 diabetes: mediating effects of cardiometabolic risk factors. <b>2019</b> , 62, 2211-2221	25
1030	Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. <b>2019</b> , 1864, 158523	12

1029	Somatotropic Axis and Obesity: Is There Any Role for the Mediterranean Diet?. <b>2019</b> , 11,	16
1028	Very light physical activity amount in FTO genetically predisposed obese individuals. <b>2019</b> , 15, 689-697	
1027	Metabolomics: a search for biomarkers of visceral fat and liver fat content. <b>2019</b> , 15, 139	5
1026	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <b>2019</b> , 153, 169-177	
1025	Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults. <b>2019</b> , 16, 75-83	16
1024	The association between adherence to the Mediterranean diet and hepatic steatosis: cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study. <b>2019</b> , 17, 19	24
1023	The Mexican consensus on nonalcoholic fatty liver disease. <b>2019</b> , 84, 69-99	15
1022	[Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population]. <b>2019</b> , 36, 130-136	
1021	Retinol binding protein 4 and risk of type 2 diabetes in Singapore Chinese men and women: a nested case-control study. <b>2019</b> , 16, 3	9
1020	Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes. <b>2019</b> , 8,	8
1019	Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. <b>2019</b> , 95, 109677	14
1018	Copeptin relates to a fatty liver and measures of obesity in a South African population with mixed ethnicities. <b>2019</b> , 65, 304-311	6
1017	Fatty Liver Among Adolescent Offspring of Women With Type 1 Diabetes (the EPICOM Study). <b>2019</b> , 42, 1560-1568	4
1016	Metabolic Characteristics of a Novel Ultrasound Quantitative Diagnostic Index for Nonalcoholic Fatty Liver Disease. <b>2019</b> , 9, 7922	3
1015	Hepatic Fat Content and Liver Enzymes Are Associated with Circulating Free and Protein-Bound Advanced Glycation End Products, Which Are Associated with Low-Grade Inflammation: The CODAM Study. <b>2019</b> , 2019, 6289831	7
1014	Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults?. <b>2019</b> , 9, 716-722	10
1013	Efficacy of a non-invasive model in predicting the cardiovascular morbidity and histological severity in non-alcoholic fatty liver disease. <b>2019</b> , 13, 2272-2278	13
1012	A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). <b>2019</b> , 11,	39

1011	Bile Acid and Fibroblast Growth Factor 19 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Sleeve Gastrectomy. <b>2019</b> , 8,	19
1010	The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. <b>2019</b> , 71, 379-388	80
1009	The association between lecithin-cholesterol acyltransferase activity and fatty liver index. <b>2019</b> , 56, 583-592	1
1008	Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. <b>2019</b> , 20,	72
1007	The impact of the sleep duration on NAFLD score in Korean middle-aged adults: a community-based cohort study. <b>2019</b> , 57, 144-150	12
1006	Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. <b>2019</b> , 11,	88
1005	Prospective study of gestational diabetes and fatty liver scores 9 to 16 years after pregnancy. <b>2019</b> , 11, 895-905	6
1004	Emerging Circulating Biomarkers for The Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis. <b>2019</b> , 423-448	4
1003	The haemoglobin glycation index is associated with nonalcoholic fatty liver disease in healthy subjects. <b>2019</b> , 91, 271-277	6
1002	Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. <b>2019</b> , 156, 1264-1281.e4	447
1001	Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. <b>2019</b> , 15, e8793	94
1000	Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults. <b>2019</b> , 11,	11
999	Advanced oxidation protein products play critical roles in liver diseases. <b>2019</b> , 49, e13098	11
998	Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. <b>2019</b> , 39, 1343-1354	8
997	The Mexican consensus on nonalcoholic fatty liver disease. <b>2019</b> , 84, 69-99	1
996	Non-Alcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: Role of Circulating Branched-Chain Amino Acids. <b>2019</b> , 11,	31
995	Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. <b>2019</b> , 25, 1307-1326	79
994	Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. <b>2019</b> , 43, 31-45	60

993	Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people. <b>2019</b> , 51, 1330-1336	9
992	Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. <b>2019</b> , 62, 127-134	27
991	Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil. <b>2019</b> , 284, 59-65	10
990	Nonalcoholic Fatty Liver Disease. <b>2019</b> , 523-546	
989	NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter. <b>2019</b> , 70, 1302-1303	2
988	Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study. <b>2019</b> , 36, 923-949	12
987	The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010-2011. <b>2019</b> , 12, 181-190	19
986	Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. <b>2019</b> , 16, 285-291	8
985	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. <b>2019</b> , 45, 480-487	22
984	Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort. <b>2019</b> , 6, e000219	3
983	Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio Ischaemic Heart Disease Risk Factor Study Cohort. <b>2019</b> , 9, e031420	2
982	Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease. <b>2019</b> , 3, 1704-1705	
981	HIV-Associated NAFLD: Disease Burden and Management. <b>2019</b> , 18, 482-491	0
980	Altilix Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. <b>2019</b> , 11,	21
979	Hepatic Steatosis Index Is Associated with Type 1 Diabetes Complications. <b>2019</b> , 12, 2405-2410	2
978	Sex- and Age-Related Differences in the Contribution of Ultrasound-Measured Visceral and Subcutaneous Abdominal Fat to Fatty Liver Index in Overweight and Obese Caucasian Adults. <b>2019</b> , 11,	3
977	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. <b>2019</b> , 11,	14
976	The ZJU index is a powerful surrogate marker for NAFLD in severely obese North American women. <b>2019</b> , 14, e0224942	5

975	Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. <b>2019</b> , 17, 408		3
974	Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis. <b>2019</b> , 27, 104415		1
973	Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference. <b>2019</b> , 31, 998-1003		1
972	A newly noninvasive model for prediction of non-alcoholic fatty liver disease: utility of serum prolactin levels. <i>BMC Gastroenterology</i> , <b>2019</b> , 19, 202	3	5
971	Exercise Training as a Treatment for Cardiometabolic Risk in Sedentary Adults: Are Physical Activity Guidelines the Best Way to Improve Cardiometabolic Health? The FIT-AGEING Randomized Controlled Trial. <b>2019</b> , 8,		7
970	NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities. <b>2019</b> , 18, 425-432		4
969	A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. <b>2019</b> , 33, 1105-1115		9
968	Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome. <b>2019</b> , 132, 2670-2676		10
967	Physical Activity, Fatty Liver, and Glucose Metabolism Over the Life Course: The Lifelines Cohort. <b>2019</b> , 114, 907-915		10
966	Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup. <b>2019</b> , 10, 1-8		15
965	Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study. <b>2019</b> , 8,		6
964	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. <b>2019</b> , 7, 313-324		322
963	Both WHR and FLI as Better Algorithms for Both Lean and Overweight/Obese NAFLD in a Chinese Population. <b>2019</b> , 53, e253-e260		5
962	High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study. <b>2019</b> , 29, 191-200		13
961	Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. <b>2019</b> , 6, 1801585		66
960	Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes. <b>2019</b> , 68, 188-197		26
959	Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results). <b>2019</b> , 66, 31-41		17
958	Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus. <b>2019</b> , 62, 238-248		35



957	Association of thirty-year alcohol consumption typologies and fatty liver: Findings from a large population cohort study. <b>2019</b> , 194, 225-229	4
956	Effect of a weight-loss stabilization following a weight reduction with or without meal replacement on cardiometabolic risk in overweight women. A randomized controlled trial. <b>2019</b> , 70, 453-466	
955	Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. <b>2019</b> , 114, 453-463	38
954	Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. <b>2019</b> , 27, 41-49	109
953	A simpler diagnostic formula for screening nonalcoholic fatty liver disease. <b>2019</b> , 64, 18-23	3
952	Clinical workup of fatty liver for the primary care provider. <b>2019</b> , 131, 19-30	2
951	Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol. <b>2019</b> , 60, 168-175	12
950	Periodontitis is associated with incident chronic liver disease-A population-based cohort study. <b>2019</b> , 39, 583-591	22
949	Reducing NAFLD-screening time: A comparative study of eight diagnostic methods offering an alternative to ultrasound scans. <b>2019</b> , 39, 187-196	12
948	Individual fatty acids in erythrocyte membranes are associated with several features of the metabolic syndrome in obese children. <b>2019</b> , 58, 731-742	15
947	Flavonoid intake from fruit and vegetables during adolescence is prospectively associated with a favourable risk factor profile for type 2 diabetes in early adulthood. <b>2019</b> , 58, 1159-1172	21
946	Dietary polyunsaturated fatty acids mediate the inverse association of stearoyl-CoA desaturase activity with the risk of fatty liver in dyslipidaemic individuals. <b>2019</b> , 58, 1561-1568	3
945	Prediction of Liver Steatosis Applying a New Score in Subjects from the Brazilian Longitudinal Study of Adult Health. <b>2020</b> , 54, e1-e10	2
944	Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial. <b>2020</b> , 59, 477-483	41
943	Novel predictive models using serum ceruloplasmin levels for hepatic steatosis in patients with chronic hepatitis B infection. <b>2020</b> , 44, 57-65	3
942	A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease. <b>2020</b> , 119, 173-181	10
941	The correlation between fatty liver disease and chronic kidney disease. <b>2020</b> , 119, 42-50	9
940	Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran. <b>2020</b> , 39, 468-474	11



939	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <b>2020</b> , 41,	56
938	Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). <b>2020</b> , 71, 1182-1197	4
937	Association between periodontal status and non-alcoholic fatty liver disease in a Korean adult population: A nationwide cross-sectional study. <b>2020</b> , 91, 524-532	8
936	Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts. <b>2020</b> , 71, 835-848	45
935	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. <b>2020</b> , 22, 393-403	30
934	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. <b>2020</b> , 105,	19
933	Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. <b>2020</b> , 35, 1057-1064	18
932	Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. <b>2020</b> , 35, 833-839	35
931	Association between non-alcoholic fatty liver disease and risk of new-onset atrial fibrillation in healthy adults. <b>2020</b> , 40, 338-346	8
930	Obesity-induced nucleosome release predicts poor cardio-metabolic health. <b>2019</b> , 12, 2	9
929	miR-10b and miR-223-3p in serum microvesicles signal progression from prediabetes to type 2 diabetes. <b>2020</b> , 43, 451-459	21
928	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. <b>2020</b> , 95, 513-520	5
927	Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease. <b>2020</b> , 29, 205-208	6
926	Rhythmic Fluctuations in Levels of Liver Enzymes During Menstrual Cycles of Healthy Women and Effects of Body Weight. <b>2020</b> , 18, 2055-2063.e2	
925	Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy. <b>2020</b> , 41, 554-560	9
924	The effect of a Mediterranean diet on metabolic parameters in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. <b>2020</b> , 35, 40-46	21
923	Circulating total bilirubin and risk of non-alcoholic fatty liver disease in the PREVEND study: observational findings and a Mendelian randomization study. <b>2020</b> , 35, 123-137	13
922	Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. <b>2020</b> , 25, e12756	4

921	A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. <b>2020</b> , 8,	3
920	FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population. <b>2020</b> , 10, 15814	0
919	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. <b>2020</b> , 10,	9
918	A Critical Appraisal of the Definition of Sarcopenia in Patients with Non-Alcoholic Fatty Liver Disease: Pitfall of Adjusted Muscle Mass by Body Weight. <b>2020</b> , 10,	1
917	Urinary Resveratrol Metabolites Output: Differential Associations with Cardiometabolic Markers and Liver Enzymes in House-Dwelling Subjects Featuring Metabolic Syndrome. <b>2020</b> , 25,	0
916	MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. <b>2020</b> , 40, 3018-3030	95
915	Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. <b>2020</b> , 18, 261	30
914	Selecting the best machine learning algorithm to support the diagnosis of Non-Alcoholic Fatty Liver Disease: A meta learner study. <b>2020</b> , 15, e0240867	5
913	Association between non alcoholic fatty liver disease, metabolic and vascular risk. <b>2020</b> , 32, 200-205	0
912	Cardiovascular risk, Metabolic disease and NASH control for Health Empowerment: Future endeavours. <b>2020</b> , 32, 206-208	
911	Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus. <b>2020</b> , 32,	1
910	Development and validation of a UPLC-MS/MS method to quantify fructose in serum and urine. <b>2020</b> , 1155, 122299	4
909	Week 2020 Poster Presentations. <b>2020</b> , 8, 144-887	3
908	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <b>2020</b> , 14, 889-919	142
907	Correlation between the small dense LDL level and nonalcoholic fatty liver disease: Possibility of a new biomarker. <b>2020</b> , 99, e21162	3
906	Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study. <b>2020</b> , 11, 964-970	0
905	NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. <b>2020</b> , 12, 60	104
904	The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. <b>2020</b> , 3, e00127	4

903	Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. <b>2020</b> , 72, 1556-1568	21
902	Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. <b>2020</b> , 4, 1136-1148	21
901	Mediterranean Personalized Diet Combined with Physical Activity Therapy for the Prevention of Cardiovascular Diseases in Italian Women. <b>2020</b> , 12,	8
900	Agreement Between the Prevalence of Nonalcoholic Fatty Liver Disease Determined by Transient Elastography and Fatty Liver Indices. <b>2020</b> ,	4
899	Aumento aislado de la actividad sérica de la gamma-glutamilttransferasa. <b>2020</b> , 24, 1-6	
898	Validation of a Non-Laboratory Based Screening Tool for Predicting Non-Alcoholic Fatty Liver Disease in an Egyptian Setting. <b>2020</b> , 360, 662-677	3
897	Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China. <b>2020</b> , 99, e23360	2
896	Fructose-Induced Intestinal Microbiota Shift Following Two Types of Short-Term High-Fructose Dietary Phases. <b>2020</b> , 12,	10
895	Inflammatory mediators in the adipo-renal axis: leptin, adiponectin, and soluble ICAM-1. <b>2020</b> , 319, F469-F475	0
894	Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles. <b>2020</b> , 19, 126	6
893	Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity. <b>2020</b> , 73, 1482-1495	10
892	Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016. <b>2020</b> , 167, 108358	14
891	Leberbezogene Effekte von Exenatid und Dapagliflozin bei Typ-2-Diabetes. <b>2020</b> , 16, 533-534	
890	An integrative machine learning approach to discovering multi-level molecular mechanisms of obesity using data from monozygotic twin pairs. <b>2020</b> , 7, 200872	0
889	Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. <b>2021</b> , 12, 1272-1277	6
888	The Development and Implementation of a Commissioned Pathway for the Identification and Stratification of Liver Disease in the Community. <b>2020</b> , 11, 86-92	17
887	Higher cut-off values of non-invasive methods might be needed to detect moderate-to-severe steatosis in morbid obese patients: a pilot study. <b>2020</b> , 10, 15007	1
886	Clinical characterization of data-driven diabetes subgroups in Mexicans using a reproducible machine learning approach. <b>2020</b> , 8,	12

885	Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). <b>2021</b> , 38, e14395	13
884	Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. <b>2020</b> , 3, e00177	6
883	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. <b>2020</b> , 15, e0237430	5
882	The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). <b>2020</b> , 2020, 3920196	40
881	FABP1 and FABP2 as markers of diabetic nephropathy. <b>2020</b> , 17, 2338-2345	13
880	Very Low-Carbohydrate Ketogenic Diet for the Treatment of Severe Obesity and Associated Non-Alcoholic Fatty Liver Disease: The Role of Sex Differences. <b>2020</b> , 12,	10
879	Liver Expressed Antimicrobial Peptide 2 is Associated with Steatosis in Mice and Humans. <b>2021</b> , 129, 601-610	4
878	A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <b>2020</b> , 37, 4627-4640	2
877	Comparative Assessment and External Validation of Hepatic Steatosis Formulae in a Community-Based Setting. <b>2020</b> , 9,	7
876	Fruit and vegetable consumption and non-alcoholic fatty liver disease among Korean adults: a prospective cohort study. <b>2020</b> , 74, 1035-1042	3
875	Metabolic Footprint, towards Understanding Type 2 Diabetes beyond Glycemia. <b>2020</b> , 9,	4
874	Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease. <b>2020</b> , 73, 1264-1265	7
873	Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). <b>2020</b> , 12, 126	7
872	Acute Coronary Syndromes and Nonalcoholic Fatty Liver Disease: "Un Affaire de Coeur". <b>2020</b> , 2020, 8825615	3
871	Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance. <b>2020</b> , 8, 1414	1
870	The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES). <b>2020</b> , 17,	7
869	Dallas steatosis index zur Vorhersage der nichtalkoholischen Fettlebererkrankung. <b>2020</b> , 16, 749-750	
868	Thyroid Function and the Risk of Non-Alcoholic Fatty Liver Disease in Morbid Obesity. <b>2020</b> , 11, 572128	8

867	Control del riesgo cardiovascular, la enfermedad metabólica y la esteatosis hepática a través del empoderamiento de la salud: una propuesta de futuro. <b>2020</b> , 32, 206-208	1
866	Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. <b>2020</b> , 11, 2042018820958298	6
865	Development and validation of screening scores of non-alcoholic fatty liver disease in middle-aged and elderly Chinese. <b>2020</b> , 169, 108385	2
864	Association between non alcoholic fatty liver disease, metabolic and vascular risk. <b>2020</b> , 32, 200-205	0
863	Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. <b>2020</b> , 19, 51	19
862	Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. <b>2020</b> , 159, 791-793.e2	10
861	Changes in Serum Nesfatin-1 After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Nonalcoholic Fatty Liver Disease. <b>2020</b> , 13, 1459-1464	2
860	Right Ventricular Free Wall Strain and Congestive Hepatopathy in Patients with Acute Worsening of Chronic Heart Failure: A CATSTAT-HF Echo Substudy. <b>2020</b> , 9,	3
859	Prevalence of Metabolic Syndrome and Nonalcoholic Fatty Liver Disease among Premenopausal and Postmenopausal Women in Ho Municipality: A Cross-Sectional Study. <b>2020</b> , 2020, 2168381	4
858	Adherence to a plant-based diet in relation to adipose tissue volumes and liver fat content. <b>2020</b> , 112, 354-363	9
857	Common and Unique Factors and the Bidirectional Relationship Between Chronic Kidney Disease and Nonalcoholic Fatty Liver in Type 2 Diabetes Patients. <b>2020</b> , 13, 1203-1214	6
856	Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?. <b>2020</b> , 6, 9	25
855	Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men. <b>2020</b> , 21,	10
854	Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease. <b>2020</b> , 14, 808-816	4
853	Heightened Plasma Levels of Transforming Growth Factor Beta (TGF- $\beta$ ) and Increased Degree of Systemic Biochemical Perturbation Characterizes Hepatic Steatosis in Overweight Pediatric Patients: A Cross-Sectional Study. <b>2020</b> , 12,	4
852	Oxidative stress is associated with suspected non-alcoholic fatty liver disease and all-cause mortality in the general population. <b>2020</b> , 40, 2148-2159	16
851	Light-to-Moderate Alcohol Consumption Is Associated With Increased Risk of Type 2 Diabetes in Individuals With Nonalcoholic Fatty Liver Disease: A Nine-Year Cohort Study. <b>2020</b> , 115, 876-884	9
850	The Preoperative Dietary Inflammatory Index Predicts Changes in Cardiometabolic Risk Factors After 12 Months of Roux-en-Y Gastric Bypass. <b>2020</b> , 30, 3932-3939	1

849	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. <b>2020</b> , 17, e1003149	18
848	Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016. <b>2020</b> , 287, 711-722	23
847	Liver enzyme variability and risk of heart disease and mortality: A nationwide population-based study. <b>2020</b> , 40, 1292-1302	12
846	Prevalence of pre-diabetes and undiagnosed diabetes in the Mollerussa prospective observational cohort study in a semi-rural area of Catalonia. <b>2020</b> , 10, e033332	5
845	The risk factors for hepatic steatosis in patients with primary aldosteronism. <b>2020</b> , 67, 623-629	2
844	Negative Energy Balance Induced by Exercise or Diet: Effects on Visceral Adipose Tissue and Liver Fat. <b>2020</b> , 12,	5
843	Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial. <b>2020</b> , 71, 991-1000	4
842	Association between Fatty Liver Index and Periodontitis: the Korea National Health and Nutrition Examination Survey. <b>2020</b> , 10, 3805	7
841	Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. <b>2020</b> , 76, 562-568	14
840	Association between periodontal disease, tooth loss and liver diseases risk. <b>2020</b> , 47, 1053-1063	15
839	Risk Prediction for Non-alcoholic Fatty Liver Disease Based on Biochemical and Dietary Variables in a Chinese Han Population. <b>2020</b> , 8, 220	4
838	Biomarkers of exposure and early effect in three contaminated sites of southern Italy: protocols for etiological epidemiological studies. <b>2020</b> , 10, e036160	4
837	Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. <b>2020</b> , 21,	15
836	Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study. <b>2020</b> , 40, 2252-2262	9
835	Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. <b>2020</b> , 37, 1793-1806	5
834	5-Lipoxygenase Derivatives as Serum Biomarkers of a Successful Dietary Intervention in Patients with NonAlcoholic Fatty Liver Disease. <b>2020</b> , 56,	1
833	Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. <b>2020</b> , 17, 182-190	14
832	Association Between Fatty Liver Index and Risk of Breast Cancer: A Nationwide Population-Based Study. <b>2020</b> , 20, e450-e457	6

831	Burden of Disease due to Nonalcoholic Fatty Liver Disease. <b>2020</b> , 49, 1-23	22
830	Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. <b>2020</b> , 9,	17
829	Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. <b>2020</b> , 77, 20-25	10
828	The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study. <b>2020</b> , 15, e0226351	12
827	Association of increased hepatic insulin clearance and change in serum triglycerides or Dihydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin. <b>2020</b> , 22, 947-956	6
826	Fatty liver in pregnancy: a narrative review of two distinct conditions. <b>2020</b> , 14, 127-135	8
825	Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. <b>2020</b> , 43, 1019-1026	5
824	Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease. <b>2020</b> , 18, 2073-2080.e7	13
823	3D Optical Imaging as a New Tool for the Objective Evaluation of Body Shape Changes After Bariatric Surgery. <b>2020</b> , 30, 1866-1873	5
822	The Effect of Zinc Supplementation on Steatosis Severity and Liver Function Enzymes in Overweight/Obese Patients with Mild to Moderate Non-alcoholic Fatty Liver Following Calorie-Restricted Diet: a Double-Blind, Randomized Placebo-Controlled Trial. <b>2020</b> , 197, 394-404	5
821	Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea. <b>2020</b> , 20, 204	11
820	Association of the rs7359397 Gene Polymorphism with Steatosis Severity in Subjects with Obesity and Non-Alcoholic Fatty Liver Disease. <b>2020</b> , 12,	4
819	A life-time of hazardous drinking and harm to health among older adults: findings from the Whitehall II prospective cohort study. <b>2020</b> , 115, 1855-1866	7
818	Noninvasive Diagnosis of NAFLD and NASH. <b>2020</b> , 9,	55
817	Incidence of type 2 diabetes in familial combined hyperlipidemia. <b>2020</b> , 8,	4
816	Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome. <b>2020</b> , 2020, 3534042	6
815	The Impact of Bariatric Surgery on Hepatic Function and Predictors of Liver Steatosis and Fibrosis. <b>2020</b> , 30, 2935-2941	3
814	Combined effects of lifestyle risk factors on fatty liver index. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 109	3 4



813	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <b>2020</b> , 115, 584-595	24
812	Association between dietary sodium intake and non-alcoholic fatty liver disease in the US population. <b>2021</b> , 24, 993-1000	5
811	The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial. <b>2021</b> , 75, 99-111	12
810	Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men. <b>2021</b> , 44, 819-842	6
809	Clinical utility of transient elastography as an imaging tool to assess the short-term impact of laparoscopic sleeve gastrectomy, together with clinical and biochemical parameters and clinico-biochemical indices, on obese patients with nonalcoholic fatty liver disease: An Egyptian pilot study. <b>2021</b> , 86, 125-132	
808	A novel model for predicting fatty liver disease by means of an artificial neural network. <b>2021</b> , 9, 31-37	2
807	Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. <b>2021</b> , 143, 82-91	2
806	A branched-chain amino acid-based metabolic score can predict liver fat in children and adolescents with severe obesity. <b>2021</b> , 16, e12739	5
805	Serum C-X-C motif chemokine ligand 14 levels are associated with serum C-peptide and fatty liver index in type 2 diabetes mellitus patients. <b>2021</b> , 12, 1042-1049	1
804	SeP is elevated in NAFLD and participates in NAFLD pathogenesis through AMPK/ACC pathway. <b>2021</b> , 236, 3800-3807	7
803	Non-invasive diagnosis of non-alcoholic fatty liver disease using an algorithm combining clinical indexes and ultrasonographic measures. <b>2021</b> , 21, 100264	1
802	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <b>2021</b> , 74, 775-782	50
801	Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity. <b>2021</b> , 19, 167-173	10
800	Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. <b>2021</b> , 52, 25-37	25
799	Validation of fatty liver disease scoring systems for ultrasound diagnosed non-alcoholic fatty liver disease in adolescents. <b>2021</b> , 53, 746-752	2
798	Association between nonalcoholic fatty liver and increased low-level albuminuria in postmenopausal women in China: A cross-sectional study. <b>2021</b> , 13, 494-505	1
797	Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China. <b>2021</b> , 36, 1326-1333	0
796	(C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle. <b>2021</b> , 3, 100203	4



795	Angiotensin-like 8 (ANGPTL8) as a potential predictor of NAFLD in paediatric patients with Prader-Willi Syndrome. <b>2021</b> , 44, 1447-1456	2
794	The Plasma Metabolomic Profile is Differently Associated with Liver Fat, Visceral Adipose Tissue, and Pancreatic Fat. <b>2021</b> , 106, e118-e129	2
793	Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature. <b>2021</b> , 44, 957-968	2
792	The association of low-grade albuminuria with incident non-alcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycaemia status. <b>2021</b> , 41, 101-109	3
791	CT and MR imaging evaluation of living liver donors. <b>2021</b> , 46, 17-28	2
790	Lean NAFLD: an underrecognized and challenging disorder in medicine. <b>2021</b> , 22, 351-366	5
789	Composite BMI and Waist-to-Height Ratio Index for Risk Assessment of Non-alcoholic Fatty Liver Disease in Adult Populations. <b>2021</b> , 20,	1
788	Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes. <b>2021</b> , 18, 3280-3289	2
787	Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment. <b>2021</b> , 9, 35	2
786	Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). <b>2021</b> , 53, 1256-1264	2
785	Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM). <b>2021</b> , 68, 905-918	1
784	Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999-2016. <b>2021</b> , 53, 1065-1073	2
783	Food insecurity is associated with magnetic resonance-determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV. <b>2021</b> , 113, 593-601	7
782	A sociodemographic, anthropometric and lifestyle-based prediction score for screening children with overweight and obesity for hepatic steatosis: The HEPAKID index. <b>2021</b> , 16, e12770	
781	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. <b>2021</b> , 11,	3
780	Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication. <b>2021</b> ,	0
779	Relevance of fructose intake in adolescence for fatty liver indices in young adulthood. <b>2021</b> , 60, 3029-3041	3
778	SYSTEMATIC REVIEW WITH COMPARATIVE ANALYSIS OF RECOMMENDATIONS FOR THE DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE. <b>2021</b> , 107-112	

777	Biological and psychological stress correlates are linked to glucose metabolism, obesity and gender roles in women. <b>2021</b> ,		1
776	Childhood and Adulthood Passive Smoking and Nonalcoholic Fatty Liver in Midlife: A 31-year Cohort Study. <b>2021</b> , 116, 1256-1263		1
775	Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study. <b>2021</b> , 60, 3043-3057		0
774	Differences in dietary intakes and overall diet quality by risk for non-alcoholic fatty liver disease in US adults. <b>2021</b> , 80,		
773	Association between nutrient patterns and fatty liver index: Baseline survey of the Japan Multi-Institutional Collaborative Cohort Study in Tokushima, Japan. <b>2021</b> ,		0
772	Diagnostic accuracy assessment of molecular prediction model for the risk of NAFLD based on MRI-PDFF diagnosed Chinese Han population. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 88	3	1
771	Diabetes mellitus und Fettlebererkrankungen. <b>2021</b> , 16, 109-119		
770	Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study. <b>2021</b> , 15, 482-492		2
769	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. <b>2021</b> , 41, 731-742		4
768	Effect of a 12-Week Concurrent Training Intervention on Cardiometabolic Health in Obese Men: A Pilot Study. <b>2021</b> , 12, 630831		1
767	Associations of Serum Fatty Acid Proportions with Obesity, Insulin Resistance, Blood Pressure, and Fatty Liver: The Cardiovascular Risk in Young Finns Study. <b>2021</b> , 151, 970-978		5
766	Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. <b>2021</b> , 22, 445-456		1
765	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). <b>2021</b> , 19, 1147-1156		1
764	Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. <b>2021</b> , 11, 2884		3
763	External Validation of Surrogate Indices of Fatty Liver in the General Population: the Bagnacavallo Study. <b>2021</b> , 10,		5
762	Cardiometabolic Profile of Different Body Composition Phenotypes in Children. <b>2021</b> , 106, e2015-e2024		2
761	Valoraci3n bioqu3mica en la enfermedad hep3tica grasa asociada a la disfunci3n metab3lica. <b>2021</b> , 2, 209-219		
760	Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. <b>2021</b> , 10,		11

759	Fatty liver index is associated with the risk of testosterone deficiency in aging men without metabolic syndrome. <b>2021</b> , 9, 863-872	1
758	The Impact of Vitamin D in Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Patients with Morbid Obesity. <b>2021</b> , 14, 487-495	4
757	From heterogeneous healthcare data to disease-specific biomarker networks: A hierarchical Bayesian network approach. <b>2021</b> , 17, e1008735	4
756	Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. <b>2021</b> , 11, 3737	7
755	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults. <b>2021</b> , 1	2
754	Circulating chemerin level is associated with metabolic, biochemical and haematological parameters-A population-based study. <b>2021</b> , 94, 927-939	2
753	Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. <b>2021</b> , 39, 961-969	0
752	Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study. <b>2021</b> , 12, 599339	2
751	Utility of quantitative ultrasound in community screening for hepatic steatosis. <b>2021</b> , 111, 106329	1
750	Fibroblast growth factor 21 levels and liver inflammatory biomarkers in obese subjects after weight loss. <b>2022</b> , 18, 36-44	1
749	Prevalence of non-alcoholic fatty liver disease and its associated factors in individuals with type 1 diabetes: a cross-sectional study in a tertiary care center in Brazil. <b>2021</b> , 13, 33	3
748	Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <b>2021</b> , 43, 455-472	2
747	The performance of noninvasive indexes of adults in identification of nonalcoholic fatty liver disease in children. <b>2021</b> , 13, 744-753	1
746	Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. <b>2021</b> , 41, 1556-1564	3
745	Association between nonalcoholic fatty liver disease and cardiovascular disease revealed after comprehensive control of metabolic risk factors: a nationwide population-based study in Korea. <b>2021</b> ,	1
744	Analysis of factors associated with discrepancies between predicted and observed liver weight in liver transplantation. <b>2021</b> , 41, 1379-1388	4
743	Uncertain association between maximal fat oxidation during exercise and cardiometabolic risk factors in healthy sedentary adults. <b>2021</b> , 1-11	2
742	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. <b>2021</b> , 12, 649496	7

741	Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. <b>2021</b> , 66, 2092-2100	1
740	PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy. <b>2021</b> , 10,	0
739	The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease. <b>2021</b> , 10,	3
738	Nurse-led telephone intervention for lifestyle changes on glycaemic control in people with prediabetes: Study protocol for a randomized controlled trial. <b>2021</b> , 77, 3204-3217	0
737	Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. <b>2021</b> , 27, 959-975	8
736	Biochemical assessment of metabolic associated fatty liver disease. <b>2021</b> , 2, 199-208	1
735	Circulating Glycerolipids, Fatty Liver Index, and Incidence of Type 2 Diabetes: A Prospective Study Among Chinese. <b>2021</b> , 106, 2010-2020	3
734	Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. <b>2021</b> , 1, 4-52	31
733	Dynamic Chronological Changes in Serum Triglycerides Are Associated With the Time Point for Non-alcoholic Fatty Liver Disease Development in the Nationwide Korean Population Cohort. <b>2021</b> , 8, 637241	0
732	Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. <b>2021</b> , 41, 1532-1544	5
731	Is there any useful surrogate to evaluate metabolic fatty liver disease?. <b>2021</b> , 84, 344-345	0
730	The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study. <b>2021</b> , 12, 638615	7
729	Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <b>2021</b> ,	10
728	Glucose Variability and Risk of Hepatocellular Carcinoma in Patients with Diabetes: A Nationwide Population-Based Study. <b>2021</b> , 30, 974-981	2
727	US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score?. <b>2021</b> , 132, 204-209	5
726	Controlled Attenuation Parameter in Healthy Individuals Aged 8-70 Years. <b>2021</b> , 7, E6-E13	
725	Non Alcoholic Fatty Liver Disease Is Positively Associated with Increased Glycated Haemoglobin Levels in Subjects without Diabetes. <b>2021</b> , 10,	3
724	Liver fat scores do not reflect interventional changes in liver fat content induced by high-protein diets. <b>2021</b> , 11, 8843	0

723	Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. <b>2021</b> , 10,	2
722	Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis. <b>2021</b> , 10,	5
721	NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management. <b>2021</b> , 76, 450-466	0
720	Development and Internal Validation of Fatty Liver Prediction Models in Obese Children and Adolescents. <b>2021</b> , 10,	2
719	Utility of Fatty Liver Index to predict reversion to normoglycemia in people with prediabetes. <b>2021</b> , 16, e0249221	2
718	Update on cardiovascular risk in nonalcoholic fatty liver disease. <b>2021</b> , 36, 478-486	0
717	Clinical utility of transient elastography as an imaging tool to assess the short-term impact of laparoscopic sleeve gastrectomy, together with clinical and biochemical parameters and clinico-biochemical indices, on obese patients with nonalcoholic fatty liver disease: An Egyptian pilot study. <b>2021</b> , 86, 125-132	
716	Fatty Liver Disease Prediction Model Based on Big Data of Electronic Physical Examination Records. <b>2021</b> , 9, 668351	0
715	Serum butyrylcholinesterase/HDL-cholesterol ratio and atherogenic index of plasma in patients with fatty liver disease. <b>2021</b> , 67, e04-e08	1
714	Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects. <b>2021</b> , 11, 8606	3
713	Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review. <b>2021</b> , 9, 727	0
712	Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. <b>2021</b> ,	7
711	Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. <b>2021</b> , 10,	3
710	Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. <b>2021</b> , 11, 9154	2
709	Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. <b>2021</b> , 13,	17
708	Effects of Insoluble Cereal Fibre on Body Fat Distribution in the Optimal Fibre Trial. <b>2021</b> , 65, e2000991	1
707	Associations between nut intake, cognitive function and non-alcoholic fatty liver disease (NAFLD) in older adults in the United States: NHANES 2011-14. <b>2021</b> , 21, 313	4
706	Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. <b>2021</b> , 215, 77-82	3

705	Non-invasive diagnosis of non-alcoholic fatty liver disease using an algorithm combining clinical indexes and ultrasonographic measures. <b>2021</b> , 22, 100335		
704	Correlation of the Fatty Liver Index with the Pathophysiological Abnormalities Associated with Cardiovascular Risk Markers in Japanese Men without any History of Cardiovascular Disease: Comparison with the Fibrosis-4 Score. <b>2021</b> , 28, 524-534	2	
703	CUN-BAE Index as a Screening Tool to Identify Increased Metabolic Risk in Apparently Healthy Normal-Weight Adults and Those with Obesity. <b>2021</b> , 151, 2215-2225		1
702	Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study). <b>2021</b> , 1		2
701	Leberfettindices reflektieren Leberfettänderungen bei Patienten mit Typ-2-Diabetes nur sehr eingeschränkt. <b>2021</b> , 16,		
700	De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study. <b>2021</b> , 10,		1
699	Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases. <b>2021</b> , 10, 521-533		
698	A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test. <b>2021</b> , 20, 54		0
697	Serum iron and risk of nonalcoholic fatty liver disease and advanced hepatic fibrosis in US adults. <b>2021</b> , 11, 10387		0
696	Effects of garlic powder supplementation on metabolic syndrome components, insulin resistance, fatty liver index, and appetite in subjects with metabolic syndrome: A randomized clinical trial. <b>2021</b> , 35, 4433-4441		3
695	Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. <b>2021</b> , 11,		0
694	Association between aspartate aminotransferase-to-alanine aminotransferase ratio and insulin resistance among US adults. <b>2021</b> ,		1
693	Association between toothbrushing and non-alcoholic fatty liver disease. <b>2021</b> , 16, e0243686		2
692	Association of meat consumption with NAFLD risk and liver-related biochemical indexes in older Chinese: a cross-sectional study. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 221	3	4
691	Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations. <b>2021</b> , 9, 494-502		0
690	Uncovering undiagnosed liver disease: prevalence and opportunity for intervention in a population attending colonoscopy. <b>2021</b> , 8,		0
689	Portal venous and hepatic artery hemodynamic variation in non-alcoholic fatty liver disease. <b>2021</b> , 11,		
688	Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study. <b>2021</b> , 150, 73-82		2

687	Quantification of glycoproteins by nuclear magnetic resonance associated with preclinical carotid atherosclerosis in patients with type 1 diabetes. <b>2021</b> , 31, 2099-2108	2
686	Nonalcoholic fatty liver disease is associated with the development of obstructive sleep apnea. <b>2021</b> , 11, 13473	1
685	Early life factors and their relevance for markers of cardiometabolic risk in early adulthood. <b>2021</b> , 31, 2109-2121	
684	A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. <b>2021</b> ,	12
683	High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects. <b>2021</b> , 11, 12830	2
682	Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. <b>2021</b> , 11,	0
681	Brown Adipose Tissue, Adiposity, and Metabolic Profile in Preschool Children. <b>2021</b> , 106, 2901-2914	3
680	Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease. <b>2021</b> , 41, 2371-2382	5
679	Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools. <b>2021</b> , 15, 812-820	0
678	Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort. <b>2021</b> , 51, e13627	2
677	Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic Syndrome. <b>2021</b> , 53, 529-540	2
676	Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. <b>2021</b> , 119, 154770	20
675	Association of PAF and its Metabolic Enzymes with GGT and the Fatty Liver Index in Healthy Volunteers. <b>2021</b> , 19, 663-672	0
674	Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. <b>2021</b> , 41, 225-234	5
673	Association of hepatic steatosis derived from ultrasound and quantitative MRI with prediabetes in the general population. <b>2021</b> , 11, 13276	1
672	TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population. <b>2021</b> , 10,	1
671	Short-Term Changes in Metabolically Healthy Overweight/Obesity Status Impact the Susceptibility to Type 2 Diabetes in Chinese Adults. <b>2021</b> , 14, 2561-2571	1
670	Aumento isolato dell'attività sierica della gamma-glutamyl-transferasi. <b>2021</b> , 23, 1-6	



669	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. <b>2021,</b>	0
668	Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. <b>2021,</b> 41, 2590-2600	2
667	Increase in testosterone levels is related to a lower risk of conversion of prediabetes to manifest diabetes in prediabetic males. <b>2021,</b> 1	3
666	Glycemic variability and the risk of nonalcoholic fatty liver disease : A nationwide population-based cohort study. <b>2021,</b> 177, 108922	1
665	The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. <b>2021,</b> 116, 2068-2078	2
664	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <b>2021,</b>	9
663	Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study. <b>2021,</b> 19, 376-386	1
662	Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. <b>2021,</b>	1
661	Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10-Year Period in Both Male and Female Subjects. <b>2021,</b> 10, e021430	1
660	Diagnosis of Nonalcoholic Steatohepatitis.	
659	Dose-dependent effects of insoluble fibre on glucose metabolism: a stratified post hoc analysis of the Optimal Fibre Trial (OptiFiT). <b>2021,</b> 58, 1649-1658	1
658	Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease. <b>2021,</b> 46, 101755	2
657	Effect of hepatic steatosis on native T1 mapping of 3T magnetic resonance imaging in the assessment of T1 values for patients with non-alcoholic fatty liver disease. <b>2021,</b> 80, 1-8	2
656	Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics. <b>2021,</b> 5, 2068-2079	1
655	Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. <b>2021,</b> 177, 108882	0
654	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <b>2021,</b> 27, 363-401	21
653	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. <b>2021,</b> 11, 13844	3
652	Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. <b>2021,</b> 5, 1676-1688	6



651	MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. <b>2021</b> , 51, 1115-1128	21
650	Effect of a Training Program on Hepatic Fat Content and Cardiometabolic Risk in Postmenopausal Women: The Randomized Controlled Trial. <b>2021</b> , 11, 6409	0
649	Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. <b>2021</b> , 60, 2167-2174	4
648	Correlation Between 25 Hydroxyvitamin D Levels and Nonalcoholic Fatty Liver Disease in Chinese Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study. <b>2021</b> , 14, 3099-3107	1
647	Ameliorates Non-Alcoholic Fatty Liver Disease by Inhibiting Oxidative Stress-Mediated Steatosis and Apoptosis through NRF2-ARE Activation. <b>2021</b> , 10,	4
646	Prediction of Cardiovascular Risk Using Nonalcoholic Fatty Liver Disease Scoring Systems. <b>2021</b> , 9,	0
645	Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean national health and nutrition examination survey (KNHANES). <b>2021</b> , 29, 1111-1118	1
644	Current Options and Future Directions for NAFLD and NASH Treatment. <b>2021</b> , 22,	12
643	Personalized Postprandial Glucose Response-Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes. <b>2021</b> , 44, 1980-1991	9
642	What's New in Hepatic Steatosis. <b>2021</b> , 42, 405-415	2
641	Application of computer tongue image analysis technology in the diagnosis of NAFLD. <b>2021</b> , 135, 104622	7
640	Increased Risk of Nonalcoholic Fatty Liver Disease in Individuals with High Weight Variability. <b>2021</b> , 36, 845-854	1
639	Negative interaction of fatty liver and hypertension on cardiovascular mortality in non-diabetic men: 34 years of follow-up. <b>2021</b> , 56, 1096-1102	
638	Genetic predisposition, lifestyle risk, and obesity associate with the progression of nonalcoholic fatty liver disease. <b>2021</b> , 53, 1435-1442	3
637	Elevated Serum Cyclophilin D Level is Associated with Nonalcoholic Fatty Liver Disease and Higher Fibrosis Scores in Patients with Diabetes Mellitus. <b>2021</b> , 14, 4665-4675	2
636	Independent Association of Fatty Liver Index With Left Ventricular Diastolic Dysfunction in Subjects Without Medication. <b>2021</b> , 158, 139-146	0
635	Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. <b>2021</b> , 87, 204-240	10
634	Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease. <b>2021</b> , 12, 707505	0

633	Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: A randomized controlled trial. <b>2021</b> , 44, 130-135	6
632	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. <b>2021</b> , 21, 1065-1078	1
631	The associations between physical activity intensity, cardiorespiratory fitness, and non-alcoholic fatty liver disease. <b>2021</b> ,	0
630	Alcohol consumption and mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. <b>2021</b> , 335, 119-125	3
629	Is there an 'ideal' diet for patients with NAFLD?. <b>2021</b> , e13659	2
628	Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults. <b>2021</b> , 9,	1
627	Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity. <b>2021</b> , 37, 1867-1873	0
626	Genetic Polymorphism of Vitamin D Family Genes , , and Are Associated With a High Risk of Non-alcoholic Fatty Liver Disease: A Case-Control Study. <b>2021</b> , 12, 717533	1
625	Fixed combination of ramipril and indapamide in patients with hypertension and non-alcoholic fatty liver disease: focus on the large arteries. <b>2021</b> , 27, 365-375	
624	Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. <b>2021</b> , 27, 4913-4928	1
623	Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies. <b>2021</b> , 93, 883-889	1
622	Noninvasive Evaluation of Liver Fibrosis in a Sample of Putative Inactive HBV Carriers in Rome, Italy. <b>2021</b> , 2021, 3068690	
621	Identification of 90 NAFLD GWAS loci and establishment of NAFLD PRS and causal role of NAFLD in coronary artery disease.. <b>2022</b> , 3, 100056	0
620	Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study. <b>2021</b> , 11, 16453	0
619	The Association Between Coffee Consumption and Nonalcoholic Fatty Liver Disease in the South Korean General Population. <b>2021</b> , 65, e2100356	1
618	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. <b>2021</b> , 18,	2
617	Improvement of Lipid Profile after One-Anastomosis Gastric Bypass Compared to Sleeve Gastrectomy. <b>2021</b> , 13,	1
616	Fatty liver index and progression to type 2 diabetes: a 5-year longitudinal study in Spanish workers with pre-diabetes. <b>2021</b> , 11, e045498	1

615	Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts. <b>2021</b> , 36, 823-834	1
614	Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease. <b>2021</b> ,	0
613	Nonalcoholic fatty liver disease and the risk of insulin-requiring gestational diabetes. <b>2021</b> , 13, 90	1
612	Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease.. <b>2022</b> , 10, 164-173	2
611	Effects of a Calorie-Restricted Mediterranean-Style Diet on Plasma Lipids in Hypercholesterolemic South Korean Patients. <b>2021</b> , 13,	0
610	Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. <b>2021</b> , 3, 100381	1
609	Polymorphism Is Associated With Physical Activity-Mediated Metabolic Changes in Type 2 Diabetes. <b>2021</b> , 12, 693683	1
608	Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. <b>2021</b> , 75, 524-535	15
607	The Association between Branched-Chain Amino Acids (BCAAs) and Cardiometabolic Risk Factors in Middle-Aged Caucasian Women Stratified According to Glycemic Status. <b>2021</b> , 13,	1
606	Association of elevated serum aminotransferase levels with chronic kidney disease measures: hispanic community health study/study of latinos. <b>2021</b> , 22, 302	1
605	Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis. <b>2021</b> , 75, 726-728	2
604	Determinants of elevated chemerin as a novel biomarker of immunometabolism: data from a large population-based cohort. <b>2021</b> , 10, 1200-1211	2
603	Fatty liver index as a predictive marker for the development of diabetes: A retrospective cohort study using Japanese health check-up data. <b>2021</b> , 16, e0257352	1
602	The association of hepatic steatosis and fibrosis with heart failure and mortality. <b>2021</b> , 20, 197	4
601	Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. <b>2021</b> , 29, 1950-1960	10
600	Serum Afamin a Novel Marker of Increased Hepatic Lipid Content. <b>2021</b> , 12, 670425	3
599	Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?. <b>2021</b> , 12, 1479-1493	1
598	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <b>2021</b> , 1	

- 597 Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. **2021**, 35, 107978 1
- 596 Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. **2021**, 321, G252-G261 1
- 595 Low Circulating Concentrations of Very Long Chain Saturated Fatty Acids Are Associated with High Risk of Mortality in Kidney Transplant Recipients. **2021**, 13,
- 594 Non-alcoholic fatty liver disease: A patient guideline. **2021**, 3, 100322 17
- 593 Use of human PBMC to analyse the impact of obesity on lipid metabolism and metabolic status: a proof-of-concept pilot study. **2021**, 11, 18329 3
- 592 Intake of Nuts and Seeds Is Associated with a Lower Prevalence of Nonalcoholic Fatty Liver Disease in US Adults: Findings from 2005-2018 NHANES. **2021**, 151, 3507-3515 1
- 591 Nonalcoholic Fatty Liver Disease. **2021**, 6, 667-675
- 590 Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea. **2021**, 123, 154866 6
- 589 Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. **2021**, 19, 2138-2147.e10 59
- 588 Diabetes and metabolic dysfunction-associated fatty liver disease. **2021**, 123, 154868 1
- 587 The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study. **2021**, 45, 101567 1
- 586 Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes. **2021**, 124, 154874 4
- 585 Links between gut microbiome composition and fatty liver disease in a large population sample. **2021**, 13, 1-22 12
- 584 Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine. **2021**, 45, 22 4
- 583 Sleeve Gastrectomy in Non-alcoholic Steatohepatitis (NASH) and Liver Cirrhosis. **2021**, 115-137
- 582 Diagnostic Considerations in Metabolic Disease Associated with Obstructive Sleep Apnea. **2021**, 57-66
- 581 Design and Conduct of a Real-World Single-Center Registry Study on Testosterone Therapy of Men with Hypogonadism. **2021**, 2, 1-17 1
- 580 Predicting Non-Alcoholic Fatty Liver Disease for Adults Using Practical Clinical Measures: Evidence from the Multi-ethnic Study of Atherosclerosis. **2021**, 36, 2648-2655 0

579	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <b>2021</b> , 17, 12	16
578	Management of non-alcoholic fatty liver disease. <b>2021</b> , 372, m4747	31
577	Mining Longitudinal Epidemiological Data to Understand a Reversible Disorder. <b>2014</b> , 120-130	6
576	Hepatic Biomarkers in Diabetes as Modulated by Dietary Phytochemicals. <b>2017</b> , 957-975	3
575	Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. <b>2020</b> , 55, 731-741	11
574	The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants. <b>2020</b> ,	17
573	Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. <b>2020</b> , 1, 100154	8
572	Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study. <b>2020</b> , 23, 1553-1563	3
571	Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial. <b>2021</b> , 113, 391-400	9
570	A prospective cohort study of the use of the fatty liver index and Fibroscan to determine the prevalence of fatty liver disease in an Irish population. <b>2020</b> , 34,	1
569	Early prediction of liver disease using conventional risk factors and gut microbiome-augmented gradient boosting.	10
568	Links between gut microbiome composition and fatty liver disease in a large population sample.	2
567	The Dutch Microbiome Project defines factors that shape the healthy gut microbiome.	6
566	Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. <b>2020</b> , 8,	35
565	Prospective association between adherence to the Mediterranean diet and hepatic steatosis: the Swiss CoLaus cohort study. <b>2020</b> , 10, e040959	2
564	Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents. <b>2018</b> , 3,	53
563	Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. <b>2020</b> , 10,	10
562	Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus non-invasive assessment scores in patients with non-alcoholic fatty liver disease. <b>2020</b> , 10,	5

561	Fatty Acid Metabolism and Associations with Insulin Sensitivity Differs Between Black and White South African Women. <b>2021</b> , 106, e140-e151	1
560	Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. <b>2012</b> , 7, e32710	40
559	Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers. <b>2013</b> , 8, e76813	8
558	Hepatic rather than cardiac steatosis relates to glucose intolerance in women with prior gestational diabetes. <b>2014</b> , 9, e91607	5
557	Insulin-like growth factor 1 predicts post-load hypoglycemia following bariatric surgery: a prospective cohort study. <b>2014</b> , 9, e94613	24
556	Associations between longer habitual day napping and non-alcoholic fatty liver disease in an elderly Chinese population. <b>2014</b> , 9, e105583	15
555	Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. <b>2015</b> , 10, e0124749	38
554	Phenotype, Body Composition, and Prediction Equations (Indian Fatty Liver Index) for Non-Alcoholic Fatty Liver Disease in Non-Diabetic Asian Indians: A Case-Control Study. <b>2015</b> , 10, e0142260	11
553	A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study. <b>2015</b> , 10, e0143560	42
552	Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate. <b>2015</b> , 10, e0143851	4
551	Fatty Liver Index Associates with Relative Sarcopenia and GH/IGF-1 Status in Obese Subjects. <b>2016</b> , 11, e0145811	28
550	Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease. <b>2016</b> , 11, e0160526	18
549	The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori. <b>2016</b> , 11, e0166741	9
548	Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort. <b>2018</b> , 13, e0194153	28
547	Irisin and markers of metabolic derangement in non-diabetic Caucasian subjects with stage I-II obesity during early aging. <b>2020</b> , 15, e0229152	3
546	Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. <b>2021</b> , 9, 71-80	4
545	Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. <b>2021</b> , 116, 116-124	20
544	Reproducibility of ultrasound attenuation imaging for the noninvasive evaluation of hepatic steatosis. <b>2020</b> , 39, 121-129	23

543	Increased serum fetuin-B concentration is associated with HOMA- $\beta$ and indices of liver steatosis in women with polycystic ovary syndrome: a pilot study. <b>2019</b> , 8, 1159-1167	5
542	The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. <b>2014</b> , 9, 10-15	6
541	Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease. <b>2018</b> , 110, 634-640	7
540	Relationship between plasma S-Klotho and cardiometabolic risk in sedentary adults. <b>2020</b> , 12, 2698-2710	7
539	Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. <b>2016</b> , 7, 35632-35642	15
538	Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. <b>2020</b> , 8, 1583	2
537	An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study. <b>2020</b> , 29, 22-29	13
536	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. <b>2021</b> , 44, 511-518	6
535	Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. <b>2018</b> , 109, 418-428	52
534	Older age and HDL-cholesterol as independent predictors of liver fibrosis assessed by BARD score. <b>2019</b> , 110, 191-198	12
533	Predictive Values of Serum Uric Acid and Alanine-aminotransferase for Fatty Liver Index in Montenegrin Population. <b>2019</b> , 38, 407-417	7
532	Is endocan a novel potential biomarker of liver steatosis and fibrosis?. <b>2020</b> , 39, 363-371	3
531	Preliminary results of dulaglutide treatment in patients with non-alcoholic fatty liver disease (DEMOS study). <b>2020</b> , 4-10	1
530	Non-Alcoholic Fatty Liver Disease and Its Association with Depression in Korean General Population. <b>2019</b> , 34, e199	21
529	Development and Validation of a Simple Index Based on Non-Enhanced CT and Clinical Factors for Prediction of Non-Alcoholic Fatty Liver Disease. <b>2020</b> , 21, 413-421	4
528	Endocrine disruptors, obesity, and cytokines - how relevant are they to PCOS?. <b>2020</b> , 69, S279-S293	11
527	Perspectives of nonalcoholic fatty liver disease research: a personal point of view. <b>2020</b> , 1, 85-107	10
526	Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. <b>2014</b> , 20, 3655-62	28

525	Epidemiology of fatty liver: an update. <b>2014</b> , 20, 9050-4	59
524	Endocrine causes of nonalcoholic fatty liver disease. <b>2015</b> , 21, 11053-76	43
523	Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality. <b>2015</b> , 21, 13555-65	7
522	Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. <b>2015</b> , 21, 1650-62	79
521	Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. <b>2016</b> , 22, 3023-30	53
520	Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. <b>2020</b> , 26, 1792-1804	11
519	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. <b>2020</b> , 35, 243-259	5
518	Prediction of NAFLD occurrence in prediabetes patients. <b>2020</b> , 20, 190	8
517	Association between high fatty liver index and development of colorectal cancer: a nationwide cohort study with 21,592,374 Korean. <b>2020</b> , 35, 1354-1363	2
516	A Close Relationship between Non-Alcoholic Fatty Liver Disease Marker and New-Onset Hypertension in Healthy Korean Adults. <b>2020</b> , 50, 695-705	5
515	Spleen size in patients with metabolic syndrome and its relation to metabolic and inflammatory parameters. <b>2018</b> , 30, 78-82	3
514	Neck Circumference to Height Ratio is a Reliable Predictor of Liver Stiffness and Nonalcoholic Fatty Liver Disease in Prediabetes. <b>2018</b> , 22, 347-354	8
513	Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. <b>2019</b> , 149, 9-17	30
512	Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population. <b>2020</b> , 12, 149-159	9
511	Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. <b>2015</b> , 7, 638-48	49
510	Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. <b>2015</b> , 7, 1192-208	7
509	Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. <b>2019</b> , 13, 440-449	17
508	Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. <b>2019</b> , 13, 658-668	17



507	Serum Gamma-glutamyltransferase and Obesity: is there a Link?. <b>2018</b> , 72, 112-115	9
506	Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD). <b>2018</b> , 18,	6
505	Prevalence of Non-Alcoholic Fatty Liver and its Related Factors in Birjand, During Year 2015. <b>2016</b> , 13,	1
504	Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities. <b>2021</b> , 5, 982-987	
503	Non-alcoholic fatty liver disease, diabetes medications and blood pressure. <b>2021</b> , 12, 1809-1811	0
502	Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population. <b>2021</b> , 20, 145	0
501	Sex-Specific Effects of Vitamin D Status on the Metabolic Profile in Prediabetic Subjects. <b>2021</b> , 2021, 2811756	
500	Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. <b>2021</b> ,	1
499	Development and validation of a neural network for NAFLD diagnosis. <b>2021</b> , 11, 20240	2
498	Fatty Liver Index is Positively Associated with Arterial Stiffness in a Chinese Cohort Undergoing Health Assessment.	
497	Prevalence and predictors of elevated liver enzyme levels in Mexico: The Mexican National Health and Nutrition Survey, 2016. <b>2021</b> , 26, 100562	2
496	Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. <b>2021</b> , 56, 1022-1032	6
495	Determination of Cardiovascular Risk in 56,262 Spanish Construction Workers: Cardiovascular Risk in Construction Workers. <b>2021</b> , 63, e911-e917	
494	Short Term Caloric Restriction and Biofeedback Enhance Psychological Wellbeing and Reduce Overweight in Healthy Women. <b>2021</b> , 11,	1
493	Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease. <b>2021</b> ,	2
492	NAFLD mark: an accurate model based on microRNA-34 for diagnosis of non-alcoholic fatty liver disease patients. <b>2021</b> , 19, 157	0
491	Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. <b>2021</b> , 1-10	0
490	Hepatic steatosis is associated with anthropometry, cardio-metabolic disease risk, sex, age and urbanisation, but not with ethnicity in adult Kenyans. <b>2021</b> ,	1

- 489 Metabolic effects of ramipril and indapamide in hypertensive patients with non-alcoholic fatty liver disease. **2021**, 27, 472-481
- 488 Machine learning models for predicting non-alcoholic fatty liver disease in the general United States population: NHANES database. **2021**, 13, 1417-1427 0
- 487 Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study. **2021**, 13, 1
- 486 Cardiovascular risk and associated risk factors in Spanish professional drivers. **2021**, 23, 101266 1
- 485 12 Niet-alcoholische steatohepatitis. **2009**, 119-126
- 484 Senescent Liver. **2011**, 279-290 1
- 483 Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. **2013**, 497-506
- 482 [Non-alcoholic fatty liver disease and steatohepatitis]. **2013**, 154, 1124-34
- 481 Fructose, High Fructose Corn Syrup, Sucrose, and Nonalcoholic Fatty Liver Disease. **2014**, 325-339 1
- 480 Benefit: "therapeutic indication". **2015**, 112, 143-4
- 479 In reply. **2015**, 112, 144
- 478 Nonalcoholic Fatty Liver Disease. 2056-2069
- 477 A STUDY OF NONALCOHOLIC FATTY LIVER DISEASE AND FATTY LIVER INDEX IN TYPE 2 DIABETES MELLITUS PATIENTS. **2016**, 3, 3001-3006
- 476 Considerations on the correlation between real body and body image. **2016**, 9, 7-12 1
- 475 Wer keinen Stress hat, ist schon tot□**2017**, 15-91
- 474 Associations between fatty liver index and asymptomatic intracranial vertebrobasilar stenosis in Chinese population. **2017**, 12, e0187502 1
- 473 Leistungsffiger, erfolgreicher und glücklicher durch intelligente Ernährung. **2018**, 249-278
- 472 Diagnostic Approach. **2018**, 317-327

471	Scoring-Systeme in der Endokrinologie. <b>2018</b> , 273-287	
470	On the operational definition of fatty liver.	
469	The Comparison of Simple Anthropometric and Biochemical Parameters for Predicting Liver Steatosis in Obese Balinese Young Women. <b>2018</b> , 6, 2062-2066	
468	Non-invasive methods for detection of progressive fibrosis in patients with nonalcoholic fat liver disease. <b>2019</b> , 22, 82	1
467	The Association Between Serum Vitamin D Level and Nonalcoholic Fatty Liver Disease. <b>2019</b> , 19,	1
466	The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). <b>2019</b> , 10, 262-266	1
465	An integrative machine learning approach to discovering multi-level molecular mechanisms of obesity using data from monozygotic twin pairs.	
464	Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: A nationwide population-based study in Korea.	
463	Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population. <b>2020</b> , 17,	0
462	Noninvasive methods of diagnosis of steatosis in non-alcoholic fatty liver disease. <b>2020</b> , 174, 61-66	2
461	Comparison of Computed Tomography-based Abdominal Adiposity Indexes as Predictors of Non-alcoholic Fatty Liver Disease Among Middle-aged Korean Men and Women. <b>2020</b> , 53, 256-265	1
460	Longitudinal Associations Between Hand Grip Strength and Non-Alcoholic Fatty Liver Disease in Adults: A Prospective Cohort Study. <b>2021</b> , 8, 752999	0
459	Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. <b>2021</b> ,	6
458	Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease. <b>2021</b> , 19, 5920-5930	1
457	Biochemical Biomarkers of NAFLD/NASH. <b>2020</b> , 89-114	1
456	Detection of NAFLD/NASH in the General Population and in Primary Care Clinics. <b>2020</b> , 11-27	
455	Diagnosis of hepatic steatosis in non-alcoholic fatty liver disease in the military. <b>2020</b> , 22, 100-104	
454	Renal hyperfiltration, fatty liver index, and the hazards of all-cause and cardiovascular mortality in Finnish men. <b>2021</b> , 43, e2021001	0

- 453 Comparison of noninvasive scoring systems for the prediction of nonalcoholic fatty liver disease in metabolic syndrome patients. **2020**, 99, e23619 0
- 452 Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: A nationwide population-based study in Korea.
- 451 NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications. **2020**, 169-197
- 450 Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools. **2020**, 157-180
- 449 Non-alcoholic Fatty Liver Disease, Cardio-metabolic Syndrome and Hypertension: One Concept Fits Multi-systemic Presentations. **2020**, 50, 706-708
- 448 Ultrasound elastography in patients with fatty liver disease. **2020**, 53, 47-55 4
- 447 Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis. **2020**, 12, 4
- 446 Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: A nationwide population-based study in Korea.
- 445 Predicting and elucidating the etiology of fatty liver disease using a machine learning-based approach: an IMI DIRECT study.
- 444 Transcriptional, epigenetic and metabolic signatures in cardiometabolic syndrome defined by extreme phenotypes.
- 443 Imaging methods in the assessment of nonalcoholic fatty liver disease. **2020**, 53, IX-X
- 442 Metabolically Healthy Obesity (MHO) vs. Metabolically Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with Endocrine-Metabolic Profile, Adherence to the Mediterranean Diet, and Body Composition. **2021**, 13, 2
- 441 Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. **2021**, 22, 4
- 440 Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease. **2021**, 0
- 439 Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. **2021**, 2
- 438 Screening for Non-alcoholic Fatty Liver Disease in Current Practice. 1
- 437 Utilidad práctica de los índices no invasivos en la esteatosis hepática metabólica. **2021**, 0
- 436 First-degree family history of diabetes is associated with nonalcoholic fatty liver disease independent of glucose metabolic status. **2021**, 108083

435	Sex differences in the association between nonalcoholic fatty liver disease and Parkinson's disease. <b>2021</b> , 93, 19-26		0
434	Association between toothbrushing and non-alcoholic fatty liver disease.		
433	External validation of biomarkers of fatty liver in the general population: the Bagnacavallo study.		
432	Association of serum alanine aminotransferase levels with cardiometabolic risk factors in normal-weight and overweight children. <b>2011</b> , 21, 287-93		7
431	Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. <b>2014</b> , 7, 4191-8		16
430	Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. <b>2015</b> , 8, 17654-63		35
429	Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. <b>2018</b> , 5, e000150		5
428	Assessment of hepatic steatosis algorithms in non-alcoholic fatty liver disease. <b>2018</b> , 22, 10-16		2
427	Development and validation of a nomogram for predicting nonalcoholic fatty liver disease in the non-obese Chinese population. <b>2020</b> , 12, 6149-6159		
426	S2FLNet: Hepatic steatosis detection network with body shape. <b>2021</b> , 140, 105088		0
425	Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population.. <b>2021</b> , 11,		3
424	Anti-inflammatory diet consumption reduced fatty liver indices. <b>2021</b> , 11, 22601		3
423	Independent associations of thyroid-related hormones with hepatic steatosis and insulin resistance in euthyroid overweight/obese Chinese adults. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 431	3	2
422	Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver. <b>2021</b> ,		2
421	Dietary and Lifestyle Inflammation Scores are Inversely Associated with Metabolic-associated Fatty Liver Disease (MAFLD) among Iranian Adults: A Nested Case-Control Study. <b>2021</b> ,		0
420	Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study. <b>2021</b> , 1		3
419	The Dietary Inflammatory Index and hepatic health in the US adult population. <b>2021</b> ,		0
418	Non-invasive Risk Stratification for NAFLD Among Living Liver Donor Candidates: A Proposed Algorithm. <b>2021</b> ,		1

4 <sup>17</sup>	Evolution of Metabolic Phenotypes of Obesity in Coronary Patients after 5 Years of Dietary Intervention: From the CORDIOPREV Study. <b>2021</b> , 13,	
4 <sup>16</sup>	Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study. <b>2021</b> , 16, e0260477	0
4 <sup>15</sup>	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. <b>2021</b> ,	0
4 <sup>14</sup>	Pre-diagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma. <b>2021</b> ,	4
4 <sup>13</sup>	Outstanding improvement of the advanced lipoprotein profile in subjects with new-onset type 1 diabetes mellitus after achieving optimal glycemic control. <b>2021</b> , 182, 109145	0
4 <sup>12</sup>	Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population. <b>2021</b> ,	0
4 <sup>11</sup>	Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis.. <b>2022</b> , 12, e049767	2
4 <sup>10</sup>	Association of plasma fatty acid-binding protein 3 with estimated glomerular filtration rate in patients with type 2 diabetes mellitus.. <b>2022</b> , 19, 82-88	0
4 <sup>09</sup>	Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers.. <b>2021</b> , 127, 154955	4
4 <sup>08</sup>	INSULIN RESISTANCE AS AN INDICATOR OF DIFFERENTIATION FOR THE FORMATION OF RISK GROUPS FOR NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITHOUT TYPE 2 DIABETES MELLITUS, AS A PART OF ONTOLOGICAL MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE. <b>2021</b> , 74, 2593-2598	
4 <sup>07</sup>	A Non-invasive Diagnosis Tool Based on Hepatorenal Index For Hepatic Steatosis. <b>2021</b> ,	
4 <sup>06</sup>	A nationwide survey of the association between nonalcoholic fatty liver disease and the incidence of asthma in Korean adults.. <b>2022</b> , 17, e0262715	0
4 <sup>05</sup>	NFI, a clinical scoring tool for predicting non-alcoholic fatty liver in the Chinese population. <b>2021</b> , 202, 12-17	1
4 <sup>04</sup>	MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.. <b>2021</b> , 8, 774079	2
4 <sup>03</sup>	Associations between aflatoxin B-albumin adduct levels with metabolic conditions in Guatemala: A cross-sectional study.. <b>2022</b> , 5, e495	0
4 <sup>02</sup>	Circulating level of FABP4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. <b>2021</b> ,	0
4 <sup>01</sup>	Mediterranean Diet and Fatty Liver Risk in a Population of Overweight Older Italians: A Propensity Score-Matched Case-Cohort Study.. <b>2022</b> , 14,	0
4 <sup>00</sup>	Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease.. <b>2021</b> , 12, 775677	0

399	The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults. 1	0
398	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. 2021,	1
397	The Burden of NAFLD in Type 2 Diabetic Subjects from the General Population: a Nationwide Population-Based Follow-Up Study (NASHCO).. 2022,	0
396	Fetuin-A and risk of diabetes-related vascular complications: a prospective study.. 2022, 21, 6	1
395	Non-invasive tests of non-alcoholic fatty liver disease.. 2022, 135,	1
394	Fatty Liver Index and Skeletal Muscle Density.. 2022, 1	2
393	The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.. 2022,	0
392	Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Authors' reply.. 2022, 55, 481-482	
391	Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma?. 2022, 55, 479-480	0
390	NAFLD or MAFLD: That is the conundrum.. 2022, 21, 103-103	1
389	Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH).. 2021,	2
388	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. 2021,	1
387	Metabolically healthy obesity: Is it really healthy for type 2 diabetes mellitus?. 2022, 13, 70-84	0
386	A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease.. 2022,	0
385	Plasma Industrial and Ruminant Trans Fatty Acids and Incident Type 2 Diabetes in the EPIC-Potsdam Cohort.. 2022,	1
384	A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study.. 2022, 12, 1956	0
383	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.. 2022, 12,	2
382	The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy.. 2022, 58,	

381	Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD.. <b>2022,</b>	3
380	Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany.. <b>2022,</b>	2
379	The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.. <b>2022,</b> 12, 1896	
378	Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk.. <b>2021,</b> 12, 781789	0
377	The role of non-alcoholic fatty liver disease in the development of vascular rigidity and cardiovascular risk in patients with arterial hypertension. <b>2021,</b> 14-21	
376	Differences in cardiovascular risk levels between cleaning staff and hotel housekeepers.. <b>2022,</b> 64, e12320	1
375	Prevalence of Metabolic-associated Fatty Liver Disease in Mexico and Development of a Screening Tool: The MAFLD-S Score. <b>2022,</b> 1, 352-358	0
374	Serum Levels of IL-1 RA Increase with Obesity and Type 2 Diabetes in Relation to Adipose Tissue Dysfunction and are Reduced After Bariatric Surgery in Parallel to Adiposity.. <b>2022,</b> 15, 1331-1345	1
373	Association of plasma kynurenine pathway metabolite concentrations with metabolic health risk in prepubertal Asian children.. <b>2022,</b>	1
372	Increased Oxygen Desaturation Time During Sleep Is a Risk Factor for NASH in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study.. <b>2022,</b> 9, 808417	0
371	Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.. <b>2022,</b> 5, e220262	0
370	Sodium in relation with nonalcoholic fatty liver disease: A systematic review and meta-analysis of observational studies.. <b>2022,</b> 10, 1579-1591	1
369	Association between serum uric acid level and non-alcoholic fatty liver disease in Koreans. <b>2022,</b> 16, 15-22	0
368	Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort.. <b>2022,</b> 1	0
367	Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults.. <b>2022,</b> 11,	
366	Liver Enzymes are Associated with Hyperglycemia in Diabetes: A Three-Year Retrospective Study. Volume 15, 545-555	1
365	Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank.. <b>2022,</b> 16, 325	1
364	Gut microbiota from Mexican patients with metabolic syndrome and HIV infection: an inflammatory profile.. <b>2022,</b>	2



363	The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004.. <b>2022</b> , 14,	0
362	Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score.. <b>2022</b> ,	1
361	Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis.. <b>2022</b> , 9, 812030	0
360	Metabolic dysfunction-related liver disease as a risk factor for cancer.. <b>2022</b> , 9,	1
359	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.. <b>2022</b> ,	0
358	Non-alcoholic Fatty Liver Disease and the Risk of Incident Atrial Fibrillation in Young Adults: A Nationwide Population-Based Cohort Study.. <b>2022</b> , 9, 832023	1
357	Plasma Tsukushi Concentration Is Associated with High Levels of Insulin and FGF21 and Low Level of Total Cholesterol in a General Population without Medication.. <b>2022</b> , 12,	0
356	Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting.. <b>2022</b> ,	2
355	Multidisciplinary lifestyle intervention is associated with improvements in liver damage and in surrogate scores of NAFLD and liver fibrosis in morbidly obese patients.. <b>2022</b> ,	1
354	The triglycerides and glucose (TyG) index: a new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients.. <b>2022</b> , 101345	0
353	Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease.. <b>2022</b> , 14, 44	0
352	Transcriptional, epigenetic and metabolic signatures in cardiometabolic syndrome defined by extreme phenotypes.. <b>2022</b> , 14, 39	0
351	Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study.. <b>2022</b> , 12,	0
350	Non-Alcoholic Fatty Liver Disease and the Risk of Diabetes Mellitus by Menopausal Status: A Nationwide Cohort Study.. <b>2022</b> , 12,	0
349	The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome.. <b>2022</b> , 11,	0
348	Metabolic Dysfunction-Associated Fatty Liver Disease and Risk of Incident Chronic Kidney Disease: A Nationwide Cohort Study.. <b>2022</b> , 101344	1
347	Association of Nonalcoholic Fatty Liver Disease with Incident Dementia Later in Life Among Elder Adults.. <b>2022</b> ,	0
346	Validation of five hepatic steatosis algorithms in metabolic- associated fatty liver disease: a population based study.. <b>2022</b> ,	1

345	Circulating concentrations of free triiodothyronine are associated with central adiposity and cardiometabolic risk factors in young euthyroid adults.. <b>2022</b> , 1		0
344	Identification of hepatic steatosis in living liver donors by machine learning models.. <b>2022</b> ,		0
343	Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD.. <b>2022</b> , 1		1
342	A Machine Learning Based Framework to Identify and Classify Non-alcoholic Fatty Liver Disease in a Large-Scale Population.. <b>2022</b> , 10, 846118		0
341	Non-alcoholic fatty liver disease is not independently associated with Helicobacter pylori in a Central European screening cohort.. <b>2022</b> ,		1
340	Development of a prediction protocol for the screening of metabolic associated fatty liver disease in children with overweight or obesity.. <b>2022</b> , e12917		0
339	Assessment of interleukin 32 as a novel biomarker for non-alcoholic fatty liver disease. <b>2022</b> , 12,		
338	Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease.. <b>2022</b> , 100699		0
337	A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery.. <b>2021</b> ,		0
336	Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD.. <b>2021</b> ,		2
335	Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults.. <b>2022</b> , 30, 50-61		1
334	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury.. <b>2021</b> , 10,		0
333	Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China.. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 482	3	0
332	Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis.. <b>2021</b> , 10,		3
331	Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study.. <b>2021</b> , 13, 748888		1
330	and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation.. <b>2021</b> , 13, 1991-2004		
329	Organoprotective properties of combination therapy with ramipril and indapamide in hypertensive patients with non-alcoholic fatty liver disease. <b>2022</b> , 27, 591-601		
328	Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities.. <b>2021</b> , 12, 777075		1

327	Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease.. <b>2021</b> , 18,	1
326	Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes.. <b>2021</b> , 2021, 7956161	
325	Alcohol Consumption and Cardiovascular Outcomes in Patients With Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.. <b>2021</b> ,	0
324	A family history of type 2 diabetes as a predictor of fatty liver disease in diabetes-free individuals with excessive body weight.. <b>2021</b> , 11, 24084	1
323	Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approachThe institutional adaptation to existing Clinical Practice Guidelines. <b>2022</b> , 2, 12-22	1
322	The effect of non-alcoholic fatty liver disease on the functional state of the kidneys in patients with chronic heart failure. <b>2021</b> , 35-42	
321	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. <b>2021</b> , 1	1
320	Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. <b>2022</b> , 19, 61-77	
319	Hepatocardial relationships in patients with arterial hypertension and non-alcoholic fatty liver disease: focus on cardiac remodeling. <b>2022</b> , 25, 61	
318	DNA Methylation Patterns According to Fatty Liver Index and Longitudinal Changes from the Korean Genome and Epidemiology Study (KoGES). <b>2022</b> , 44, 1149-1168	1
317	Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study.. <b>2022</b> ,	1
316	High fibrosis-4 (FIB-4) index predicts new onset of ischemic heart disease during a 10-year period in a general population.	0
315	Ambulante Gewichtsreduktion durch Mahlzeiten-Ersatz-Therapie in der tztlichen Praxis: 2-Jahres-Ergebnisse einer nicht kontrollierten Beobachtungsstudie. <b>2022</b> , 47, 122-134	
314	A nutrigenetic tool for precision dietary management of NAFLD deeming insulin resistance markers.. <b>2022</b> ,	0
313	The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study.. <b>2022</b> , 21, 53	0
312	Environmental factors shaping the gut microbiome in a Dutch population.. <b>2022</b> ,	19
311	A Machine Learning-Based Predictive Model to Identify Patients Who Failed to Attend a Follow-up Visit for Diabetes Care After Recommendations From a National Screening Program.. <b>2022</b> ,	1
310	Association between the fatty liver index and the risk of severe complications in COVID-19 patients: a nationwide retrospective cohort study.. <b>2022</b> , 22, 384	1

- 309 Prognosis of Chronic Kidney Disease in Patients with Non-Alcoholic Fatty Liver Disease: a Northeastern Taiwan Community Medicine Research Cohort.. **2022**, 0
- 308 Image\_1.jpeg. **2020**,
- 307 Image\_2.jpeg. **2020**,
- 306 Table\_1.docx. **2020**,
- 305 Table\_1.DOCX. **2020**,
- 304 Table\_2.DOCX. **2020**,
- 303 Table\_3.DOCX. **2020**,
- 302 Table\_4.DOCX. **2020**,
- 301 General Overview About the Current Management of Nonalcoholic Fatty Liver Disease.. **2022**, 1 0
- 300 Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.. **2022**, 9
- 299 Predictors of metabolic-associated fatty liver disease (MAFLD) in adults: a population-based study in Northeastern Iran.. **2021**, 14, S102-S111
- 298 Fatty liver index for hyperuricemia diagnosis: a community-based cohort study.. **2022**, 22, 114 0
- 297 Association between birth weight, preterm birth and non-alcoholic fatty liver disease in a community-based cohort.. **2022**, 3
- 296 Hepatorenal Index by B-Mode Ratio Versus Imaging and Fatty Liver Index to Diagnose Steatosis in Alcohol-Related and Nonalcoholic Fatty Liver Disease.. **2022**, 0
- 295 Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala.. **2022**, 0
- 294 Changes in Indices of Steatosis and Fibrosis in Liver Grafts of Living Donors After Weight Reduction.. **2022**, 9, 827526
- 293 Prevalence of non-alcoholic fatty liver disease in the Russian Ural Eye and Medical Study and the Ural Very Old Study.. **2022**, 12, 7842 0
- 292 A healthy lifestyle during adolescence was inversely associated with fatty liver indices in early adulthood - findings from the DONALD cohort study.. **2022**, 1-23 0

291	CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE.. <b>2021</b> , 60, 36-52		
290	High fatty liver index is an independent predictor of ischemic heart disease during a 10-year period in a Japanese population.. <b>2022</b> ,		0
289	Breakthroughs in therapies for NASH and remaining challenges.. <b>2022</b> , 76, 1263-1278		1
288	The Effect of Diabetes and Prediabetes on the Prevalence, Complications and Mortality in Non-alcoholic Fatty Liver Disease.. <b>2022</b> ,		2
287	Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease. <b>2022</b> , 10, 1216		0
286	Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than does fatty liver or nonalcoholic fatty liver disease.		1
285	Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition: The Rotterdam Study. 10.1212/WNL.0000000000200770		0
284	Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. <b>2022</b> , 22,		0
283	Combined Effects of Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease on the Risk of Cardiovascular Disease in Patients with Diabetes. <b>2022</b> , 10, 1245		
282	MODERN METHODS OF DIAGNOSIS AND SCREENING OF NON-ALCOHOLIC FATTY LIVER DISEASE AND ITS STAGES: review. <b>2022</b> , 8, 226-231		
281	Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. <b>2022</b> ,		
280	Population-specific cut-off points of fatty liver index: a study based on the National Health and Nutrition Examination Survey data. <i>BMC Gastroenterology</i> , <b>2022</b> , 22,	3	0
279	Exercise Reduces the Risk of Chronic Kidney Disease in Individuals with Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study. <b>2022</b> , 101362		0
278	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.		0
277	Associations of serum n-3 and n-6 polyunsaturated fatty acids with prevalence and incidence of non-alcoholic fatty liver disease.		2
276	Automated Machine Learning (AutoML)-Derived Preconception Predictive Risk Model to Guide Early Intervention for Gestational Diabetes Mellitus. <b>2022</b> , 19, 6792		1
275	Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. <b>2022</b> , 21,		0
274	A larger brown fat volume and lower radiodensity are related to a greater cardiometabolic risk, especially in young men. <b>2022</b> , 187, 171-183		1

- 273 Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study. **2022**, 133, 155222 1
- 272 The Accuracy and Clinical Relevance of the Multi-echo Dixon Technique for Evaluating Changes to Hepatic Steatosis in Patients with Non-alcoholic Fatty Liver Disease Treated with Formulated Food. **2022**,
- 271 Arterial Stiffness, Biomarkers of Liver Fat, and the Development of Metabolic Dysfunction in Metabolically Healthy Population: A Prospective Study. 9,
- 270 Validity of fatty liver disease indices in the presence of alcohol consumption. 1-12
- 269 Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang. **2022**, 14, 2361 0
- 268 Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002-2012). **2022**, 14, 2367 0
- 267 Fatty Liver Index Independently Predicts All-Cause Mortality in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis but No Substantial Liver Disease. 9, 1
- 266 A Cross-Sectional Pilot Study on Food Intake Patterns Identified from Very Short FFQ and Metabolic Factors Including Liver Function in Healthy Japanese Adults. **2022**, 14, 2442 1
- 265 Impact of Physical Activity Differences Due to COVID-19 Pandemic Lockdown on Non-Alcoholic Fatty Liver Parameters in Adults with Metabolic Syndrome. **2022**, 14, 2370 0
- 264 Letter: is it appropriate to use a fatty liver index  $\geq 60$  as an alternative criterion for non-alcoholic fatty liver disease?. **2022**, 56, 376-377 0
- 263 Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. **2022**, 12, 0
- 262 Machine-Learning Algorithm for Predicting Fatty Liver Disease in a Taiwanese Population. **2022**, 12, 1026 2
- 261 Obesidad, hábitos de vida y valoración FLI en la población laboral española durante la pandemia. 93-98
- 260 Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis. **2022**, 21, 1
- 259 Letter: association of circulating bile acid concentrations and non-alcoholic fatty liver disease. **2022**, 56, 372-373 0
- 258 The Association of Toxoplasma gondii IgG and Liver Injury in US Adults. **2022**, 19, 7515 0
- 257 Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy. **2022**, 9, e000913 0
- 256 NAFLD: Mechanisms, Treatments, and Biomarkers. **2022**, 12, 824 3

- 255 Fatty liver indices and their association with glucose metabolism in pregnancy [An observational cohort study. **2022**, 189, 109942 ○
- 254 Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. **2022**, 246, 30-38 ○
- 253 Cardio-metabolic risk modeling and assessment through sensor-based measurements. **2022**, 165, 104823
- 252 The practical utility of non-invasive indices in metabolic hepatic steatosis. **2022**, 69, 418-425
- 251 External validation and comparison of simple tools to screen for nonalcoholic fatty liver disease in Chinese community population. **2022**, 34, 865-872 ○
- 250 A case report of multinodular hepatic steatosis mimicking pseudotumors of the liver. **2022**, 26,
- 249 Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease. **2022**, 2022, 1-12 ○
- 248 Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study. ○
- 247 Association between organochlorine pesticides and nonalcoholic fatty liver disease in the National Health and Nutrition Examination Survey 2003-2004. **2022**, 12, 1
- 246 Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study. ○
- 245 Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study.
- 244 Antioxidant Efficacy of a Spirulina Liquid Extract on Oxidative Stress Status and Metabolic Disturbances in Subjects with Metabolic Syndrome. **2022**, 20, 441
- 243 Prospective dietary polyunsaturated fatty acid intake is associated with trajectories of fatty liver disease: an 8-year follow-up study from adolescence to young adulthood. ○
- 242 Identification of novel targets in adipose tissue involved in non-alcoholic fatty liver disease progression. **2022**, 36, ○
- 241 Accuracy of Steatosis and Fibrosis NAFLD scores in relation to Vibration Controlled Transient Elastography: an NHANES analysis. **2022**, 101997 ○
- 240 The effect of curcumin on hepatic fat content in individuals with obesity.
- 239 Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. **2022**, 106348 1
- 238 Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity. **2022**, 108253 1

- 237 Cadmium, lead, and mercury mixtures interact with non-alcoholic fatty liver diseases. **2022**, 309, 119780 ○
- 236 Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients : what do we know so far ?. **2022**, 85, 346-357 ○
- 235 Dietary fatty acids and risk of non-alcoholic steatohepatitis: A national study in the United States. 9,
- 234 Dihydrocapsiate does not increase energy expenditure nor fat oxidation during aerobic exercise in men with overweight/obesity: a randomized, triple-blinded, placebo-controlled, crossover trial. **2022**, 19, 417-436
- 233 Prospective study of a new endoscopic duodenal-jejunal bypass sleeve in obese patients with non-alcoholic fatty liver disease (with video).
- 232 The impact of non-alcoholic fatty liver disease on sleep apnea in healthy adults: A nationwide study of Korea. **2022**, 17, e0271021 ○
- 231 Effects of oily fish and its fatty acid intake on non-alcoholic fatty liver disease development among South Korean adults. 9,
- 230 Associations between non-alcoholic fatty liver disease and cognitive impairment and the effect modification of inflammation. **2022**, 12, 1 ○
- 229 Relationship between the High Fatty Liver Index and Risk of Fracture. **2022**, 12, 1
- 228 Clinical significance of epicardial fat assessment in hypertensive patients with non-alcoholic fatty liver disease. **2022**, 28, 260-269
- 227 A Cross-Sectional Study of the Correlation Between the Atherogenic Index of Plasma and Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes. Volume 15, 2227-2234
- 226 Clinical Model for the Prediction of Severe Liver Fibrosis in Adult Patients with Type II Diabetes Mellitus. **2022**, 12, 1829 ○
- 225 Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease. **2022**, 12, 664 ○
- 224 Impact of duodenal-jejunal bypass liner (DJBL) on NAFLD in patients with obesity and type 2 diabetes mellitus. **2022**, 111806
- 223 Hepatic Steatosis and High-Normal Fasting Glucose as Risk Factors for Incident Prediabetes. **2022**, 6,
- 222 Liver biomarkers, genetic and lifestyle risk factors in relation to risk of cardiovascular disease in Chinese. 9,
- 221 European guideline on obesity care in patients with gastrointestinal and liver diseases □ Joint ESPEN/UEG guideline. **2022**, 4
- 220 Controlled Attenuation Parameter Accurately Detects Liver Steatosis in People Living with HIV. Publish Ahead of Print,



219	Association between hepatic steatosis and fibrosis indices and dietary habits, physical activity, and quality of life. <b>2022,</b>	
218	Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation. <b>2022,</b> 155294	1
217	The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018. <b>2022,</b> 54, 2259-2268	0
216	Intrahepatic Fat Content and COVID-19 Lockdown in Adults with NAFLD and Metabolic Syndrome. <b>2022,</b> 14, 3462	1
215	Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk.	2
214	Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals. <b>2022,</b> 19, 9935	0
213	Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease. <b>2022,</b>	0
212	Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. 9,	1
211	Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study. <b>2022,</b> 20,	
210	Association of serum uric acid with all-cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease.	
209	Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial. <b>2022,</b> 70, 102866	2
208	Association between Mediterranean Diet and Fatty Liver in Women with Overweight and Obesity. <b>2022,</b> 14, 3771	2
207	Etat des lieux sur la physiopathologie, le diagnostic et les traitements de la stéato-hépatite non alcoolique (NASH). <b>2022,</b>	0
206	The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. <b>2022,</b> 20,	0
205	Reduced Quality of Life in Patients with Non-Alcoholic Fatty Liver Disease May Be Associated with Depression and Fatigue. <b>2022,</b> 10, 1699	0
204	Associations between serum biomarkers and non-alcoholic liver disease: Results of a clinical study of Mediterranean patients with obesity. 9,	1
203	Associations of serum multivitamin levels with the risk of non-alcoholic fatty liver disease: A population-based cross-sectional study in U.S. adults. 9,	0
202	Machine Learning Soft Voting Algorithm for Prediction and Detection of Nonalcoholic Fatty Liver Disease.	0

- 201 Diagnostik: Algorithmus und Leberbiopsie. **2022**, 167-179 ○
- 200 Hepatitis C and NAFLD as Main Causes of Liver-Related Morbidity and Mortality in the French General Population: A Nationwide Study (NASH-CO Study). ○
- 199 Assessment of fatty liver and its correlation with glycemic control in patients with type 2 diabetes mellitus attending Dessie Comprehensive Specialized Hospital, Northeast Ethiopia. **2022**, 10, 205031212211249
- 198 Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank. **2022**, 13, 204062232211224 1
- 197 The accuracy of fatty liver index for the screening of overweight and obese children for non-alcoholic fatty liver disease in resource limited settings. **2022**, 22, ○
- 196 High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation. 13, ○
- 195 Biomarkers in Liver Disease. **2022**, 490-521 ○
- 194 Triglyceride Glucose-Waist Circumference (TyG-WC) Is a Reliable Marker to Predict Non-Alcoholic Fatty Liver Disease. **2022**, 10, 2251 ○
- 193 Association of Inflammatory and Metabolic Biomarkers with Mitral Annular Calcification in Type 2 Diabetes Patients. **2022**, 12, 1484 1
- 192 Metabolic Associated Fatty Liver Disease Better Identifying Patients at Risk of Liver and Cardiovascular Complications. ○
- 191 Association between the fatty liver index and chronic kidney disease: the population-based KORA study. ○
- 190 A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD). 9, 1
- 189 Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) [April 2022] AWMF Registration No.: 021025. **2022**, 60, e733-e801 ○
- 188 Potential role of inflammation in relation to dietary sodium and β-carotene with non-alcoholic fatty liver disease: a mediation analysis. **2022**, 12, ○
- 187 Individuals Undergoing Bariatric Surgery Ameliorate Hepatic Steatosis: Evidence from NHANES 2015-2018. ○
- 186 Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease.. ○
- 185 Investigation of the effects of wet cupping therapy on some inflammatory factors in patients affected by non-alcoholic fatty liver disease (NAFLD): A quasi-experimental trial study with self-controls. ○
- 184 Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [April 2022] AWMF-Registernummer: 021025. **2022**, 60, 1346-1421 ○

183	Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: influence of obesity and disease severity. <b>2022,</b>	0
182	Isotemporal Substitution of Different Behavior Patterns with the Presence of MAFLD in Chinese Adults.	0
181	Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus Non-alcoholic fatty liver disease: a longitudinal cohort analysis. <b>2022,</b> 100762	2
180	Liver steatosis and fibrosis markers association with cardiovascular and renal damage in Japanese adults: the TMM BirThree cohort study. <b>2022,</b> 100761	0
179	NRPT reduces markers of hepatic inflammation in non-alcoholic fatty liver disease: a double-blind, placebo-controlled clinical trial.	0
178	Predictive Value of the Advanced Lipoprotein Profile and Glycated Proteins on Diabetic Retinopathy. <b>2022,</b> 14, 3932	0
177	Improving the accuracy of fatty liver index to reflect liver fat content with predictive regression modelling. <b>2022,</b> 17, e0273171	0
176	Comparison of the predictive power of adiposity indices and blood lipid indices for diagnosis of prediabetes.	0
175	Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals. 1-7	0
174	Waist-to-Hip Ratio and Inflammatory Parameters Are Associated with Risk of Non-Alcoholic Fatty Liver Disease in Patients with Morbid Obesity. <b>2022,</b> 10, 2416	0
173	Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk. 13,	0
172	Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). <b>2022,</b> 21, 3356	0
171	Investigation of the effects of wet cupping therapy on some inflammatory factors in patients affected by non-alcoholic fatty liver disease (NAFLD): A quasi-experimental trial study with self-controls.	0
170	Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. <b>2022,</b> 5, e2234221	0
169	Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality. 9,	0
168	Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn disease but not Ulcerative Colitis: a prospective cohort study.	1
167	Correlation between Liver Fat Indices and Ultrasonography to Determine Non-alcoholic Fatty Liver Disease among Diabetic Patients in Sri Lanka. 17, 15	0
166	The Spectrum and Impact of Metabolic Dysfunction in MAFLD. A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals. <b>2022,</b>	3

- 165 Does Consumption of Ultra-Processed Foods Matter for Liver Health? Prospective Analysis among Older Adults with Metabolic Syndrome. **2022**, 14, 4142 1
- 164 Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years. **2022**, 21, 0
- 163 Gamma-glutamyltransferase predicts macrovesicular liver graft steatosis: An analysis of discarded liver allografts in Finland. 1-5 0
- 162 Letter: Hepatic Fibrosis and Steatosis in Metabolic Syndrome (J Obes Metab Syndr 2022;31:61-9). **2022**, 0
- 161 Inverse Association of Fruit and Vegetable Consumption with Nonalcoholic Fatty Liver Disease in Chinese Patients with Type 2 Diabetes Mellitus. **2022**, 14, 4559 0
- 160 Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers. 1
- 159 DEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD: Analysis of 10,865 Individuals. **2022**, 11, 6205 0
- 158 Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: A Mendelian randomization study of 108,835 individuals. 13, 0
- 157 Metabolic profile predicts incident cancer: A large-scale population study in the UK Biobank. **2022**, 155342 0
- 156 Association of age at first birth and risk of non-alcoholic fatty liver disease in women: evidence from the NHANES. 0
- 155 Effect of progressive resistance training with weight loss compared with weight loss alone on the fatty liver index in older adults with type 2 diabetes: secondary analysis of a 12-month randomized controlled trial. **2022**, 10, e002950 0
- 154 Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study. **2022**, 14, 5002 0
- 153 Low plasma growth/differentiation factor 1 levels are associated with liver fibrosis in patients with stable angina. 0
- 152 High Sodium Intake, as Assessed by Urinary Sodium Excretion, Is Associated with Nonalcoholic Fatty Liver Disease or Sarcopenia. **2022**, 0
- 151 Association of Change in Smoking Status and Subsequent Weight Change with Risk of Nonalcoholic Fatty Liver Disease. **2022**, 0
- 150 Metabolic Dysfunction-Associated Fatty Liver Disease in the National Health and Nutrition Examination Survey 2017-2020: Epidemiology, Clinical Correlates, and the Role of Diagnostic Scores. **2022**, 12, 1070 0
- 149 Cardiometabolic profile of 15057 elderly Spanish workers: association of sociodemographic variables and tobacco consumption. **2022**, 22, 1
- 148 Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study. **2022**, 22, 1

147	Noninvasive tests for nonalcoholic fatty liver disease in a multi-ethnic population: The HELIUS study.	0
146	Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. <b>2022</b> , 14, 4673	2
145	Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study. <b>2022</b> , 13,	1
144	Multidisciplinary Prehabilitation and Postoperative Rehabilitation for Avoiding Complications in Patients Undergoing Resection of Colon Cancer: Rationale, Design, and Methodology of the ONCOFIT Study. <b>2022</b> , 14, 4647	0
143	Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines. 16,	0
142	Impact of Physical Activity on the Characteristics and Metabolic Consequences of Alcohol Consumption: A Cross-Sectional Population-Based Study. <b>2022</b> , 19, 15048	1
141	Nonalcoholic Fatty Liver Disease A Concise Review of Noninvasive Tests and Biomarkers. <b>2022</b> , 12, 1073	0
140	NAFLD as the metabolic hallmark of obesity.	0
139	Predicting Factors for Metabolic Non-Response to a Complex Lifestyle Intervention A Replication Analysis to a Randomized-Controlled Trial. <b>2022</b> , 14, 4721	0
138	Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. <b>2022</b> , 13, 204201882211396	0
137	Utility of Indices Obtained During Medical Checkups for Predicting Fatty Liver Disease in Non-obese People. <b>2023</b> ,	0
136	Setting up of a machine learning algorithm for the identification of severe liver fibrosis profile in the general US population cohort. <b>2023</b> , 170, 104932	1
135	Non-invasive assessment of metabolic dysfunction-associated fatty liver disease. <b>2022</b> , 13, 204201882211396	0
134	Obesidad, hábitos de vida y valoración FLI en la población laboral española durante la pandemia. 93-98	0
133	Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. <b>2022</b> , 9, 419	1
132	Fat mass index as a screening tool for the assessment of non-alcoholic fatty liver disease. <b>2022</b> , 12,	0
131	Screening strategy for nonalcoholic fatty liver disease.	0
130	The Diagnostic and Prognostic Value of the Triglyceride-Glucose Index in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-Analysis. <b>2022</b> , 14, 4969	0

129	Prolonged Use of Carnitine-Orotate Complex (Godex®) Is Associated with Improved Mortality: A Nationwide Cohort Study. <b>2022</b> , 12, 1970	0
128	Dysglycemia in young women attenuates the protective effect against fatty liver disease. 13,	0
127	Effect of Two Different Dietary Weight Loss Strategies on Risk Factors for Urinary Stone Formation and Cardiometabolic Risk Profile in Overweight Women. <b>2022</b> , 14, 5054	1
126	Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study. <b>2022</b> , 17, e0277930	0
125	Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population. <b>2022</b> , 23, 15708	1
124	Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.	0
123	The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study. <b>2022</b> , 21,	0
122	Machine learning-derived gut microbiome signature predicts fatty liver disease in the presence of insulin resistance. <b>2022</b> , 12,	0
121	The role of platelet-related parameters for the prediction of NAFLD in OSAHS patients. <b>2022</b> , 22,	0
120	Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study.	0
119	MAFLD in Obesity with Deteriorating Glucose Control.	0
118	Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. <b>2022</b> ,	1
117	Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease.	0
116	Nichtinvasive Tests zur Erfassung der Fettlebererkrankung bei Personen unterschiedlicher Ethnizität	0
115	Optimum non-invasive predictive indicators for metabolic dysfunction-associated fatty liver disease and its subgroups in the Chinese population: A retrospective case-control study. 13,	1
114	High prevalence of non-alcoholic fatty liver disease in patients with a first episode of acute ischemic stroke. Impact on disability and death. 13,	0
113	The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study. <b>2022</b> , 21,	0
112	Real-world assessment of SmartExam, a novel FibroScan computational method: A retrospective single-center cohort study.	0

111	Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities.	1
110	Development and validation of a new nomogram to screen for MAFLD. <b>2022</b> , 21,	0
109	Association between iron metabolism and non-alcoholic fatty liver disease: results from the National Health and Nutrition Examination Survey (NHANES 2017-2018) and a controlled animal study. <b>2022</b> , 19,	0
108	The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study. <b>2022</b> , 194, 110191	0
107	Increased Intake of Both Caffeine and Non-Caffeine Coffee Components Is Associated with Reduced NAFLD Severity in Subjects with Type 2 Diabetes. <b>2023</b> , 15, 4	1
106	Leveraging the future of diagnosis and management of diabetes: From old indexes to new technologies.	0
105	Whole-Genome Transcriptomics of PBMC to Identify Biomarkers of Early Metabolic Risk in Apparently Healthy People with Overweight-Obesity and in Normal-Weight Subjects. 2200503	0
104	Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study. <b>2022</b> , 194, 110187	0
103	Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease. <b>2023</b> , 21,	0
102	Association between maternal obesity, essential fatty acids and BIOMARKERS OF fetal liver function. <b>2023</b> , 102541	0
101	Effect of Metabolic Dysfunction-Associated Fatty Liver Disease on Left Ventricular Deformation and Atrioventricular Coupling in Patients With Metabolic Syndrome Assessed by MRI.	0
100	Abdominal obesity and dysglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study. 13,	0
99	The Burden of Non-Alcoholic Fatty Liver Disease in Adolescents with Polycystic Ovary Syndrome: A Case-Control Study. <b>2023</b> , 12, 557	1
98	Fatty liver index predicts the development of hypertension in a Japanese general population with and without dysglycemia.	0
97	Dietary patterns and risk of non-alcoholic fatty liver disease in Korean adults: a prospective cohort study. <b>2023</b> , 13, e065198	1
96	Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults. <b>2023</b> , 29,	0
95	Correlation between fatty liver index and estimated glomerular filtration rate in an elderly population in Yangzhou, China.	0
94	Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study. <b>2023</b> , 11, 166	1



- 93 Prevalence of non-alcoholic fatty liver disease and its association with lifestyle habits in adults in Chile: a cross-sectional study from the National Health Survey 2016-2017. 1-30 ○
- 92 Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany [First data from the German NAFLD-Registry. **2023**, 61, 60-70 ○
- 91 Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia. **2023**, 11, 10 ○
- 90 Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers. 1
- 89 Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes. **2023**, 37, 108405 ○
- 88 Artificial Intelligence in NAFLD: Will Liver Biopsy Still Be Necessary in the Future?. **2023**, 11, 117 ○
- 87 Exosomes from Short-Term High-Fat or High-Sucrose Fed Mice Induce Hepatic Steatosis through Different Pathways. **2023**, 12, 169 ○
- 86 Prognostic mathematical models of the development of chronic non-viral liver diseases. **2023**, 84-91 ○
- 85 Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses. 1
- 84 Comparative analysis of the relationship between four hepatic steatosis indices and muscle mass. **2023**, 13, ○
- 83 Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin Therapy: A 6-Year Retrospective Study. **2023**, 13, 503 ○
- 82 Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. **2023**, 15, 687 ○
- 81 The Connection between Non-Alcoholic Fatty-Liver Disease, Dietary Behavior, and Food Literacy in German Working Adults. **2023**, 15, 648 ○
- 80 Dietary inflammatory index and risk of non-alcoholic fatty liver disease and advanced hepatic fibrosis in US adults. 10, ○
- 79 FABP4 Expression in Subcutaneous Adipose Tissue Is Independently Associated with Circulating Triglycerides in Obesity. **2023**, 12, 1013 ○
- 78 Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study. **2023**, ○
- 77 Nonalcoholic fatty liver disease and cardiovascular disease. **2023**, 11-16 ○
- 76 Nonalcoholic fatty liver disease. **2023**, 83-97 ○



- 75 Abordaje comū del paciente con psoriasis y riesgo de esteatosis hepática metabólica: recomendaciones de un grupo de expertos multidisciplinar. **2023**, ○
- 74 Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. **2023**, 24, 2844 ○
- 73 Plasma proteomic signature of fatty liver disease: the Rotterdam Study. Publish Ahead of Print, ○
- 72 Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD. **2023**, 35, 394-401 ○
- 71 Combining serum uric acid and fatty liver index to improve prediction quality of nonalcoholic fatty liver disease. **2023**, 0 ○
- 70 Nuclear Magnetic Resonance-Based Lipidomics in the Assessment of Cardiometabolic Risk in Type 1 Diabetes: An Exploratory Analysis. **2023**, 14, 553-567 ○
- 69 Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria. **2023**, 12, 2126 ○
- 68 Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study. ○
- 67 Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—the Chicken or the Egg Dilemma. **2023**, 11, 1097 ○
- 66 Impact of acute consumption of beverages containing plant-based or alternative sweetener blends on postprandial appetite, food intake, metabolism, and gastro-intestinal symptoms: Results of the SWEET beverages trial. **2023**, 184, 106515 ○
- 65 NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis. **2023**, 161, 435-440 ○
- 64 The nonalcoholic fatty liver risk in prediction of unfavorable outcome after stroke: A nationwide registry analysis. **2023**, 157, 106692 ○
- 63 Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease. **2023**, 27, 373-395 ○
- 62 The Past, Present, and Future of Noninvasive Test in Chronic Liver Diseases. **2023**, 107, 397-421 ○
- 61 Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models. **2023**, 161, 114445 ○
- 60 Comparison of Machine Learning Models and the Fatty Liver Index in Predicting Lean Fatty Liver. **2023**, 13, 1407 ○
- 59 High omega-6/omega-3 fatty acid and oxylipin ratio in plasma is linked to an adverse cardiometabolic profile in middle-aged adults. **2023**, 117, 109331 ○
- 58 Liver phenotypes in PCOS : Analysis of exogenous and inherited risk factors for liver injury in two European cohorts. ○

- 57 Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments. **2023**, 29, S150-S156 ○
- 56 The Effects of Eight Weeks Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity. **2023**, 15, 825 ○
- 55 Progression of prediabetes to diabetes and its associated factors: The Fasa Adult Cohort Study (FACS). ○
- 54 Dynapenia, Muscle Quality, and Hepatic Steatosis in Patients with Obesity and Sarcopenic Obesity. **2023**, 11, 472 ○
- 53 Thyroid Hormone Receptor-Agonists in NAFLD Therapy: Possibilities and Challenges. 1
- 52 Fatty liver index has potential as a predictor of hypertension in the Japanese general population. **2023**, 46, 896-897 1
- 51 Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP). **2023**, 189, 106679 ○
- 50 Sodium-glucose Cotransporter-2 Inhibitors and Risk of Hepatocellular Carcinoma Among Patients With Type 2 Diabetes. **2023**, ○
- 49 Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017-2018. 10, ○
- 48 Non-Alcoholic Fatty Liver in Obesity with Deteriorating Glucose Control. ○
- 47 Fatty Liver and Risk of Head and Neck Cancer in Type 2 Diabetes Mellitus: A Nationwide Cohort Study. **2023**, 15, 1209 ○
- 46 Consensus Statement on the definition and classification of metabolic hyperferritinaemia. **2023**, 19, 299-310 ○
- 45 Significant Dose-Response Association of Physical Activity and Diet Quality With Mortality in Adults With Suspected NAFLD in a Population Study. **2023**, Publish Ahead of Print, ○
- 44 Association between Thyroid Hormones and Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in Obese Individuals Undergoing Bariatric Surgery. **2022**, 14, 410-421 ○
- 43 NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. ○
- 42 Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants. ○
- 41 Relationship between the Mediterranean diet and risk of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A cross-sectional analysis of the RaNCD cohort. 10, ○
- 40 Prevalence of overweight/obesity and its relationship with metabolic syndrome and fatty liver index in adult patients with type 1 diabetes. A Brazilian multicenter study. **2023**, 15, ○

- 39 TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a Prudent Dietary Pattern on Serum Triglyceride Levels. **2023**, 15, 1112 ○
- 38 Validity of fatty liver prediction scores for diagnosis of fatty liver by Fibroscan. **2023**, ○
- 37 Concurrent HCV or fatty liver in patients with chronic hepatitis B virus infection. **2023**, 581-599 ○
- 36 The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study. **2023**, 15, ○
- 35 Rationale, Design and Participants Baseline Characteristics of a Crossover Randomized Controlled Trial of the Effect of Replacing SSBs with NSBs versus Water on Glucose Tolerance, Gut Microbiome and Cardiometabolic Risk in Overweight or Obese Adult SSB Consumer: Strategies to Oppose SUGARS with Non-Nutritive Sweeteners or Water (STOP Sugars NOW) Trial and Ectopic Fat Deposition. **2023**, 23, ○
- 34 Dietary selenium intake in relation to non-alcoholic fatty liver disease assessed by fatty liver index and hepatic steatosis index; a cross-sectional study on the baseline data of prospective PERSIAN Kavar cohort study.. **2023**, 23, ○
- 33 Association of Alcohol Consumption With Liver Cancer and All-Cause Mortality in Chronic Hepatitis B Patients Without Cirrhosis. **2023**, ○
- 32 Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease. **2023**, 24, 4855 ○
- 31 Efficacy and Safety of Pentoxifylline on Patients with Non-Alcoholic Steatohepatitis; Randomized Controlled Trial. ○
- 30 Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease. ○
- 29 Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease. **2023**, ○
- 28 Nonalcoholic fatty liver disease (NAFLD) detection and deep learning in a Chinese community-based population. ○
- 27 Rapport 23-02. Le foie stéatosique non alcoolique : un défi de santé publique. **2023**, ○
- 26 Insulin resistance and hepatic steatosis in type 1 diabetes mellitus and their association with diabetic chronic complications. **2023**, 48, ○
- 25 CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease. **2023**, 23, ○
- 24 Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. 14, ○
- 23 Clinical-radiomic analysis for non-invasive prediction of liver steatosis on non-contrast CT: A pilot study. 14, ○
- 22 Association of family income to poverty ratio and vibration-controlled transient elastography quantified degree of hepatic steatosis in U.S. adolescents. 14, ○

- 21 Nonlinear correlation between fatty liver index and carotid intima media thickness among individuals undergoing health examination. 14, ○
- 20 Development and validation of an online dynamic nomogram based on the atherogenic index of plasma to screen nonalcoholic fatty liver disease. **2023**, 22, ○
- 19 Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017. ○
- 18 Non-alcoholic fatty liver and fibrosis is associated with cardiovascular structure and function in young adults. **2023**, 7, ○
- 17 Sex-specific association of body mass index and fatty liver index with prevalence of renal hyperfiltration: a cross sectional study using Japanese health check-up data. **2023**, 24, ○
- 16 Liver injury indicators and subsequent cancer development among non-fatty liver population. ○
- 15 The association between nonalcoholic fatty liver disease and corrected QT interval prolongation among generally healthy Iranian population: Fasa Cohort Study (FACS). ○
- 14 Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes. **2023**, 100753 ○
- 13 The association between fatty liver index and onset of diabetes: secondary analysis of a population-based cohort study. **2023**, 23, ○
- 12 Elevated Hepatic Steatosis Index is Associated with the Development of Adverse Maternal, but Not Adverse Neonatal, Outcomes: A Retrospective Cohort Study. Volume 15, 589-598 ○
- 11 Plasma Cytokeratin-18 Fragment Level Reflects the Metabolic Phenotype in Obesity. **2023**, 13, 675 ○
- 10 Nonalcoholic fatty liver disease and cognitive impairment: A prospective cohort study. **2023**, 18, e0282633 ○
- 9 Identification of a Novel Score for Adherence to the Mediterranean Diet That Is Inversely Associated with Visceral Adiposity and Cardiovascular Risk: The Chrono Med Diet Score (CMDS). **2023**, 15, 1910 ○
- 8 Liver biomarkers, lipid metabolites, and risk of gestational diabetes mellitus in a prospective study among Chinese pregnant women. **2023**, 21, ○
- 7 Dose-response relationship between physical activity and nonalcoholic fatty liver disease: A prospective cohort study. Publish Ahead of Print, ○
- 6 Circulating Interleukin-32 and Altered Blood Pressure Control in Individuals with Metabolic Dysfunction. **2023**, 24, 7465 ○
- 5 Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study. ○
- 4 Assessment of Performance, Interpretability, and Explainability in Artificial Intelligence-Based Health Technologies: What Healthcare Stakeholders Need to Know. **2023**, 1, 120-138 ○

- 3 Sugar-sweetened beverages, low/no-calorie beverages, fruit juice and non-alcoholic fatty liver disease defined by fatty liver index: the SWEET project. **2023**, 13, ○
- 2 Enhanced liver fibrosis test predicts liver-related outcomes in the general population. **2023**, 100765 ○
- 1 Population-Attributable Fractions of Nonalcoholic Fatty Liver Disease on All-Cause and Cause-Specific Mortality Risk: How Large is the Impact?. **2023**, ○